Crystal structure of the BTK protein and its binding pocket
By determining the three-dimensional structure of BTK's binding site and using structural coordinates to design inhibitors, the patent addresses the need for effective BTK inhibitors to treat cancer and immune diseases.
Patent Information
- Application Number
- JP2024534274
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-08
- Filing Date
- 2022-12-07
- Publication Date
- 2024-11-28
AI Technical Summary
There is a need for effective therapeutic agents that can inhibit Bruton's tyrosine kinase (BTK) to treat malignant tumors and immune diseases, as existing treatments are inadequate.
The development of crystalline compositions and methods for identifying candidate inhibitors of BTK by determining the three-dimensional structure of its binding site, using structural coordinates to design or select inhibitors, and evaluating their binding ability.
This approach enables the identification of potential inhibitors that can effectively target BTK, providing therapeutic benefits for patients with cancer and immune diseases.
Smart Images

Figure 2024544234000001_ABST
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 63 / 287,228, entitled "CRYSTAL STRUCTURE OF BTK PROTEIN AND BINDING POCKETS THEREOF," filed December 08, 2021, the entire disclosure of which is incorporated herein by reference.
[0002] (Sequence Listing) The contents of the electronic format sequence listing (PRD4173WOPCT1_Sequence Listing.xml, size 5704 bytes, created on December 5, 2022) are incorporated herein by reference in their entirety.
[0003] FIELD OF THEINVENTION The present disclosure is directed to crystalline compositions of human Bruton's tyrosine kinase ("BTK") complexed with a ligand, and methods for identifying candidate inhibitors of BTK. The present invention relates to the BTK binding pocket. The present invention also relates to methods of using structural coordinates to elucidate the structure of homologous proteins or protein complexes. Additionally, the present invention relates to methods of using structural coordinates to screen and design compounds, including inhibitor compounds that bind to BTK or complexes thereof. The present invention also relates to compounds of formula (I):
[0004] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof. [Background technology]
[0005] Malignant tumors, especially diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and other conditions such as chronic graft-versus-host disease, continue to afflict patients. Alternative and effective cancer treatments remain needed.
[0006] BTK is a 76 kDa protein that belongs to the Tec family of non-receptor tyrosine kinases. The Tec kinases form the second largest family of cytoplasmic tyrosine kinases in mammalian cells, and are composed of BTK and four other members, namely TEC, ITK, TXK / RLK, and BMX, for which the family is named. Tec kinases are evolutionarily conserved throughout vertebrates. They are related to, but structurally distinct from, the larger Src and Syk kinase families. Tec family proteins are abundantly expressed in hematopoietic tissues and play important roles in the proliferation and differentiation of mammalian blood and endothelial cells.
[0007] Based on BTK expression from IHC studies described in the art, Btk inhibition has the potential to modulate biology associated with B cells, macrophages, mast cells, osteoclasts, and platelet microparticles. Corneth, OB, et al. Curr. Top. Microbiol. Immunol. BTK Signaling in B Cell Differentiation and Autoimmunity. 2015 Sept. 5.
[0008] Therefore, there is interest in finding inhibitors of BTK that can serve as effective therapeutic agents. The new BTK ligand-bound crystal structure reveals additional hydrogen-bonding opportunities. Understanding the extent and limits of the flexibility of the binding pocket is crucial for the design of new BTK inhibitors. Summary of the Invention
[0009] Thus, there remains a need for new structural coordinates of ligand-bound BTK protein for screening and designing new ligands, including inhibitory ligands, that may provide therapeutic benefit to patients suffering from cancer and / or immune disorders. The present invention addresses this need by providing compounds and pharmaceutical compositions thereof that are effective as BTK inhibitors. Applicants have also addressed this need by providing crystal structures of BTK and BTK-inhibitor complexes. The elucidation of these crystal structures has permitted the determination of key structural features of BTK, in particular the shape of its binding pocket.
[0010] One aspect of the invention is a crystalline composition comprising the amino acid residues of SEQ ID NO:3 and a ligand, characterized in space group p22121 and with unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0011] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0012] Another aspect of the invention is a method of identifying candidate inhibitors of BTK comprising: generating on a computer a three-dimensional structure of the binding site of BTK, including the coordinates and space group parameters of a unit cell of a crystalline composition of SEQ ID NO:3; using the three-dimensional structure to design or select candidate inhibitors; and contacting the candidate inhibitors with human BTK and measuring the ability of the candidate inhibitors to bind to BTK.
[0013] A further aspect of the invention is a method of identifying and / or designing candidate inhibitors using BTK crystals comprising the BTK protein, comprising: a) preparing a crystalline composition of SEQ ID NO:3 and a ligand, wherein the ligand is a compound of Formula (I)
[0014] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof; b) soaking another candidate inhibitor in the crystalline composition to displace the compound of Formula (I) (the original ligand) and form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) using the structural coordinates obtained in step c) to design or identify a candidate inhibitor; and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0015] The present invention also provides crystallizable compositions and crystal compositions comprising BTK, with or without the presence of chemicals. The present invention also provides methods for crystallizing BTK protein or a BTK protein complex.
[0016] The invention also provides a data storage medium comprising the structural coordinates of a molecule or molecular complex of the BTK binding pocket. In one embodiment, the data storage medium comprises the structural coordinates of the binding pocket. The invention also provides a computer comprising the data storage medium. Such a storage medium, when read and utilized by a computer programmed with appropriate software, is capable of displaying a three-dimensional graphical representation of such a binding pocket on a computer screen or similar viewing device.
[0017] The present invention also provides methods for designing, evaluating and identifying compounds that bind to molecules or molecular complexes, or their binding pockets, such compounds being potential inhibitors of BTK or its homologs.
[0018] The present invention also provides methods for determining at least a portion of the three-dimensional structure of a molecule or molecular complex having at least some structurally similar characteristics to BTK, which is accomplished by using at least a portion of the structural coordinates obtained from a BTK protein or protein complex.
[0019] Some embodiments of the present invention are directed to a crystalline composition comprising SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0020] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0021] In some embodiments, a method for identifying candidate inhibitors of BTK comprises generating a three-dimensional structure of a binding site of BTK on a computer, the three-dimensional structure coordinates being determined by a compound of SEQ ID NO:3 and Formula (I):
[0022] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof. and using the three-dimensional structure to design or select a candidate inhibitor, and contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK. In some embodiments, the candidate inhibitor forms a hydrogen bond with Asp539. In some embodiments, the candidate inhibitor forms a hydrogen bond with Lys430. In some embodiments, the candidate inhibitor forms a hydrogen bond with Met477. In some embodiments, the candidate inhibitor forms hydrogen bonds with Asp539, Lys430, and Met477.
[0023] Some embodiments provide a method of identifying and / or designing candidate inhibitors using a human BTK crystal comprising a human BTK protein, the method comprising: The present invention is directed to a method comprising: a) preparing a crystalline composition comprising SEQ ID NO:3 and compound I; b) soaking another candidate inhibitor into the crystalline composition to displace the compound of formula (I) (the original ligand) and form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) using the structural coordinates obtained in step c) to design and / or identify candidate inhibitors; and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0024] Some embodiments include a method of designing a compound or complex that interacts with a binding pocket or binding domain selected from the group consisting of (i) BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, and (ii) a BTK amino acid residue according to Table 2, comprising: (a) A compound of formula (I)
[0025] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of the backbone atoms is about 2.5 Å or less; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) constructing, by model building, a compound or complex from the first chemical entity, the second chemical entity, and at least one additional chemical entity that interacts with the binding pocket or binding domain; The present invention is directed to a method, comprising:
[0026] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0027] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof. producing a crystal of BTK complexed with, wherein the BTK comprises SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of the amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root-mean-square deviation from the backbone atoms of less than ±2.0 Å; (d) determining the binding site of the human BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify candidate inhibitors that interact with the binding site.
[0028] Some embodiments further include (f) contacting the identified candidate inhibitor with a BTK protein to determine the effect of the inhibitor on BTK activity.
[0029] In some embodiments, the binding site of the BTK protein determined in step (d) comprises structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, with a root mean square deviation of less than or equal to ±2.0 Å.
[0030] Some embodiments include a method of using a crystal comprising the BTK binding pocket or the BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I)
[0031] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK binding pocket comprises SEQ ID NO:3, the crystal is characterized by space group p22121, and the unit cell parameters are a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) selecting potential inhibitors by performing rational drug design using the determined three-dimensional structure of the crystal, wherein the selecting step is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with the kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase.
[0032] Some embodiments include a method of designing a compound or complex that interacts with the BTK binding pocket or the BTK binding domain, comprising the steps of: (a) A compound of formula (I)
[0033] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0034] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0035] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structure coordinates obtained in step (b); and (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK.
[0036] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I)
[0037] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of a molecular complex comprising the binding sites for amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK. [Brief description of the drawings]
[0038] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present application and, together with the written description, serve to explain the principles, characteristics and features of the invention. [Figure 1] The chemical structure of Compound I is shown. [Diagram 2] Electron density for compound I in complex with BTK. Density is distributed throughout the compound, with clear density observed for covalent interactions including direct binding to Cys481. Light: 2fo-fc map at isosurface level 1σ (shows density for modeled atoms and unmodeled or missing atoms, no density for obviously unwanted atoms). Dark map: level.fo-fc at level + / - 3.5σ (shows positive density for unmodeled or missing atoms, negative density for unwanted atoms). [Diagram 3] The overall structure of the BTK-compound I complex is shown. Compound I is represented as a stick diagram and the BTK protein is represented as a schematic diagram. The BTK-compound I complex adopts a bilobal structural characteristic. Compound I binds to the ATP binding site, which is located in a cleft formed between the N- and C-terminal lobes of BTK, and to an adjacent region of the active site. [Figure 4] The interaction between BTK and compound I in the active site is shown. Direct binding between compound I and BTK occurs via binding to the sulfur atom of Cys481. Hydrogen bonds (dashed lines) are observed between compound I and residues Asp539, Lys430, and Met477. Solvent molecules are also observed hydrogen bonding with compound I. [Diagram 5]Detailed interactions between BTK and compound I are shown. Residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 are found in close proximity to the ligand with a maximum distance of 4.0 Å. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0039] The present disclosure may be more fully understood by reference to the following description, including the glossary below and the examples in the final section. It is also understood that certain features of the compositions and methods of the present disclosure, which are described herein in the context of separate embodiments for clarity, may be provided in combination in a single embodiment. Conversely, various features of the compositions and methods of the present disclosure, which are described in the context of a single embodiment for brevity, may be provided separately or in any subcombination. In general, those skilled in the art will understand that the terms used herein, and in particular in the appended claims (e.g., the body of the appended claims), are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to", the term "having" should be interpreted as "having at least", the term "includes" should be interpreted as "includes but is not limited to", etc.). Moreover, where a specific number is intended in an introduced claim recitation, such intent will be expressly recited in the claim, and in the absence of such recitation, one of ordinary skill in the art will understand that no such intent exists. For example, as an aid to understanding, the claims at the following appended claims may include the introductory phrases "at least one" and "one or more" to introduce the claim recitations.However, the use of such phrases should not be construed as suggesting that a claim statement introduced by the indefinite article "a" or "an" limits any particular claim containing such an introduced claim statement to an embodiment containing only one such statement, even when the same claim includes the introductory phrase "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be construed to mean "at least one" or "one or more"). The same applies when a definite article is used to introduce a claim statement. In addition, those skilled in the art will recognize that even if a specific number of introduced claim statements is explicitly recited, such a statement should be construed to mean at least the recited number (e.g., the bare statement "two statements" without other modifiers means at least two statements, or two or more statements). Furthermore, in instances where notation similar to "at least one of A, B, and C, etc." is used, such syntax is generally intended in the sense that one of ordinary skill in the art would understand such notation (e.g., "a system having at least one of A, B, and C" includes, but is not limited to, systems having only A, only B, only C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In instances where notation similar to "at least one of A, B, or C, etc." is used, such syntax is generally intended in the sense that one of ordinary skill in the art would understand such notation (e.g., "a system having at least one of A, B, or C" includes, but is not limited to, systems having only A, only B, only C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). Those skilled in the art will further appreciate that virtually all disjunctive words and / or phrases presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one of the terms, either of the terms, or both terms.For example, the phrase "A or B" is understood to include the possibilities of "A" or "B" or "A and B."
[0040] In addition, when features or aspects of the disclosure are described in terms of a Markush group, one of skill in the art will recognize that the disclosure is also thereby described in terms of any individual members or subgroups of members of the Markush group.
[0041] As will be appreciated by those of skill in the art, for all purposes, e.g., in terms of providing a written description, all ranges disclosed herein also encompass all possible subranges and combinations of those subranges. Any recited range can be readily recognized as fully descriptive and allowing for the same range to be broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third, and upper third, etc. Also, as will be appreciated by those of skill in the art, all phrases such as "up to" and "at least" refer to ranges that are inclusive of the recited numbers and that can then be broken down into subranges, as discussed above. Finally, as will be appreciated by those of skill in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to a group having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to a group having 1, 2, 3, 4, or 5 cells, etc.
[0042] Various of the above-disclosed and other features and functions, or alternatives thereof, may be combined into many other different systems or applications in which various presently unforeseen or unanticipated alternatives, modifications, variations, or improvements thereon may be made by those skilled in the art, each of which is also intended to be encompassed by the disclosed aspects.
[0043] The following abbreviations are used throughout this specification:
[0044] [Table 1]
[0045] The term "about" as used herein in connection with RMSD values allows for the standard error of the RMSD value of ±0.1 A. When "about" is used immediately preceding a numerical value, it means a range of plus or minus 10% of that value, unless otherwise indicated by the context of this disclosure or unless there is a contradiction in interpretation, e.g., "about 50" means 45-55, "about 25,000" means 22,500-27,500, etc.
[0046] The term "associated" as used herein refers to the proximity of a chemical entity or compound, or portion thereof, to a binding pocket or binding site on a protein. The association may be non-covalent (where the juxtaposition is energetically supported by hydrogen bonds or van der Waals or electrostatic interactions) or covalent.
[0047] The term "binding pocket" as used herein refers to a region of a molecule or molecular complex that, as a result of its shape and charge, favorably associates with another chemical or compound. The term "pocket" includes, but is not limited to, a cleft, a channel, or a site. BTK or a BTK-like molecule can have a binding pocket, including, but not limited to, a peptide or substrate binding site, and an antibody binding site. A binding pocket can also refer to the ATP-binding domain located at amino acid residues 389-659 of BTK and its adjacent region. A binding pocket can also refer to the ATP-binding domain of BTK represented by SEQ ID NO:3 and its adjacent region.
[0048] The term "chemical entity" as used herein refers to a compound, a complex of at least two compounds, and fragments of such compounds or complexes. For example, a chemical entity can be a ligand, a substrate, a nucleotide triphosphate, a nucleotide diphosphate, a phosphate, a nucleotide, an agonist, an agonist, an antagonist, an inhibitor, an antibody, a drug, a peptide, a protein, or a compound.
[0049] The term "compound" or "compounds" and equivalent expressions, where the context permits, refer to all compounds described herein, in particular compounds of formula (I)
[0050] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof. Similarly, reference to an intermediate, whether or not it is claimed per se, is meant to encompass its salts and solvates, where permitted by the context. The compound of formula (III) is also known as N-((1R,2S)-2-acrylamidocyclopentyl)-5-(S)-(6-isobutyl-4-methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide.
[0051] As used herein, the term "comprise", and variations such as "comprises" or "comprising", will be understood to mean the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.
[0052] The term "consisting essentially of" means that the method or composition includes the specifically recited steps or components, and may include others that do not materially affect the novel characteristics underlying the invention.
[0053] The term "consisting of" means that the method or composition includes only those steps or components specifically recited. It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise.
[0054] As used herein, the term "corresponding amino acid" or "corresponding residue" refers to a particular amino acid in a BTK protein, or an analog thereof, that is identical or functionally equivalent to an amino acid in BTK according to SEQ ID NO:3.
[0055] Methods for identifying corresponding amino acids are known in the art and are based on sequence, structural alignment, their functional location relative to BTK, or a combination thereof. For example, corresponding amino acids may be identified by superimposing the backbone atoms of the amino acids in BTK using well-known software applications such as QUANTA (Accelrys, San Diego, Calif. (©) 2001, 2002). Corresponding amino acids may also be identified using sequence alignment programs (e.g., the "Bestfit" program available from Genetics Computer Group) that use the local homology algorithm described by Smith and Waterman in Advances in Applied Mathematics 2,482 (1981), which are incorporated herein by reference.
[0056] The term "crystallization solution" as used herein refers to a solution that promotes crystallization, comprising at least one agent, including a buffer, one or more salts, a precipitating agent, one or more surfactants, a sugar or organic compound, a lanthanide ion, a polyionic compound, and / or a stabilizer.
[0057] The term "domain" as used herein refers to portions of the BTK protein that can be separated based on their biological function, e.g., based on catalysis. Domains can include binding pockets, sequences, or structural motifs.
[0058] The term "fitting operation" as used herein refers to an operation that utilizes the structural coordinates of a chemical entity, binding pocket, molecule or molecular complex, or a portion thereof, to associate the chemical entity with a binding pocket, molecule or molecular complex, or a portion thereof. This can be accomplished by positioning, rotating, or moving the chemical entity within the binding pocket to match the shape and electrostatic complementarity of the binding pocket. Non-covalent interactions such as covalent interactions, hydrogen bonds, electrostatic interactions, hydrophobic interactions, van der Waals interactions, and non-complementary electrostatic interactions such as charge-dipole repulsion interactions, dipole-dipole repulsion interactions, and charge-dipole repulsion interactions may be optimized. Alternatively, the deformation energy of binding of the chemical entity with the binding pocket may be minimized.
[0059] As used herein, the term "generating a three-dimensional structure" or "generating a three-dimensional representation" refers to converting a list of structural coordinates into a structural model or graphical representation in three-dimensional space. This can be accomplished via commercially available or publicly available software. The three-dimensional structure may be displayed or used to perform computer modeling or fitting operations. Additionally, the structural coordinates themselves may be used to perform computer modeling and fitting operations.
[0060] As used herein, the term "BTK protein" refers to the human BTK protein encoded by the BTK gene. In some embodiments, the term "BTK protein" refers to the ATP-binding domain of BTK located at amino acid residues 389-659 of BTK and adjacent regions thereof. In some embodiments, the term "BTK protein" refers to the BTK kinase domain protein represented by SEQ ID NO:3.
[0061] The term "molecular complex" or "complex" as used herein in the singular or plural form refers to a molecule in association with at least one chemical entity.
[0062] The term "motif" as used herein refers to a portion of the BTK protein that defines a structural compartment or performs a function in the protein, such as catalysis, structure stabilization, or phosphorylation. Motifs can be conserved in sequence, structure, and function. Motifs can be contiguous in primary sequence or three-dimensional space. Examples of motifs include, but are not limited to, protease domains and binding sites.
[0063] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or State government or the appropriate agency of a country other than the United States, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more specifically, in humans.
[0064] As used herein, the term "pharmaceutical acceptable salts" refers to salts of the compounds of the present disclosure that are pharma- ceutically acceptable and that possess the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and can be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with organic acids, such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, or (2) salts formed when an acidic proton present in either parent compound is replaced with a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion, or coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. Further salts include, by way of example only, salts of non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, etc., if the compound contains a basic functional group, such as sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.
[0065] The term "root mean square deviation" or "RMSD" refers to the square root of the arithmetic mean of the squares of the deviations from the mean. It is a way of expressing deviation or variation from a trend or target. For purposes of the present invention, "root mean square deviation" characterizes the variation in a protein's backbone from the BTK backbone, binding pocket, motif, domain, or portion thereof, as defined by the structural coordinates of BTK described herein. One of skill in the art will appreciate that the calculation of RMSD includes standard error.
[0066] The term "soaking" as used herein refers to the process of transferring a crystal into a solution containing the compound of interest.
[0067] The term "structural coordinates" as used herein refers to Cartesian coordinates derived from mathematical equations related to the pattern obtained by diffraction of a monochromatic beam of X-rays by the atoms (scattering centers) of a protein or protein complex in crystalline form. The diffraction data is used to calculate an electron density map of the repeating unit of the crystal. The electron density map is then used to determine the positions of the individual atoms of the molecule or molecular complex.
[0068] The term "three-dimensional structural information" as used herein refers to information obtained from structural coordinates. The structural information generated can include a three-dimensional structure or a graphical representation of a structure. Structural information can also be generated when subtracting distances between atoms in the structural coordinates, calculating chemical energies for a BTK molecule or a BTK molecular complex, or a homolog thereof, and calculating or minimizing energies for the association of a BTK molecule or a BTK molecular complex, or a homolog thereof, to a chemical entity.
[0069] As used herein, the term "treating" or "treatment" of any disease or disorder refers, in one aspect, to ameliorating the disease or disorder (i.e., arresting or reducing the onset of the disease or the manifestation of at least one of the clinical symptoms of the disease). In another aspect, "treating" or "treatment" refers to ameliorating at least one physical parameter that may not be discernible by the subject. In yet another aspect, "treating" or "treatment" refers to modulating the disease or disorder physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of physical parameters), or both. In yet another aspect, "treating" or "treatment" refers to delaying the onset of the disease or disorder.
[0070] Crystallizable compositions and crystals of BTK and its complexes In one aspect, the invention provides a crystal or crystallizable composition comprising a BTK kinase domain or a BTK kinase domain complexed with a ligand. In one aspect, the ligand is a compound of formula (I):
[0071] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0072] The BTK kinase domain in the crystal or in the crystallizable composition comprises SEQ ID NO: 3. In another embodiment, the BTK kinase domain comprises amino acid residues 389-659 of the BTK protein.
[0073] One embodiment is a crystalline composition comprising SEQ ID NO:3 and a ligand, characterized in space group p22121 and with unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0074] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0075] One embodiment is a crystalline composition comprising BTK complexed with a ligand. The disclosure provides a crystalline composition comprising BTK amino acid residues 389-659 and a ligand, the crystalline composition being characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0076] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0077] According to one aspect, the invention provides a crystal or crystallizable composition consisting essentially of a BTK kinase domain or a BTK kinase domain complexed with a ligand. In one aspect, the ligand is a compound of formula (I):
[0078] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0079] The BTK kinase domain in the crystal or crystallizable composition consists essentially of SEQ ID NO: 3. In another embodiment, the BTK kinase domain consists essentially of amino acid residues 389-659 of the BTK protein.
[0080] In one embodiment is a crystalline composition consisting essentially of SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the compound of formula (I)
[0081] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0082] One embodiment is a crystalline composition consisting essentially of BTK complexed with a ligand. The disclosure provides a crystalline composition consisting essentially of BTK amino acid residues 389-659 and a ligand, characterized in space group p22121 and with unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0083] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0084] In one aspect, the present invention provides a crystal or crystallizable composition comprising a BTK kinase domain complexed with a ligand. In one aspect, the ligand is a compound of formula (I):
[0085] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0086] The BTK kinase domain in the crystal or crystallizable composition consists of SEQ ID NO: 3. In another embodiment, the BTK kinase domain consists essentially of amino acid residues 389-659 of the BTK protein.
[0087] One embodiment is a crystalline composition consisting of SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0088] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0089] In one embodiment, the ligand is a crystalline composition comprising BTK having amino acid residues 389-659 of BTK and a ligand, characterized in space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0090] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0091] The crystal structure of BTK complexed with Compound I bound to the binding site provides important structural information for the development of novel BTK inhibitors. The present invention is a crystalline composition comprising SEQ ID NO:3 and Compound I, characterized by a space group p22121 and having unit cell parameters a=38.155±2Å, b=72.394±2Å, c=103.946±2Å, a=90°, b=90°, g=90°. The present invention includes a crystalline composition consisting essentially of SEQ ID NO:3 and Compound I, characterized by a space group p22121 and having unit cell parameters a=38.155±2Å, b=72.394±2Å, c=103.946±2Å, a=90°, b=90°, g=90°. The present invention includes a crystalline composition consisting of SEQ ID NO:3 and Compound I, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°.
[0092] Those skilled in the art will recognize that modifications at the C-terminus and N-terminus, as well as substitutions including mutations, glycosylations, acylations and methylations of some amino acid residues are possible, all of which are considered equivalents within the scope of the invention.
[0093] One embodiment is a crystalline composition or crystal comprising BTK in the presence or absence of a chemical entity. Preferably, the chemical entity is a compound of formula (I):
[0094] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0095] It will be readily apparent to one of ordinary skill in the art that the unit cell of the crystalline composition may deviate from the above lattice dimensions by ±1-2 Å depending on deviations in the unit cell calculations.
[0096] In one embodiment, the crystallizable composition comprises a crystallization solution of BTK protein, a salt, a buffer solution of pH 5.0-7.0, 0-10 mM DTT, and polyethylene glycol. The salts include, but are not limited to, KCl, LiSO4, NaCl, and (NH4)2SO4. The polyethylene glycols include, but are not limited to, PEG3350, PEGMME550, PEGMME2000, PEG4000, and PEG6000. If the crystals are derived from a seeding technique, the concentration of polyethylene glycol may be less than 35%. In another aspect, the crystallizable composition comprises a crystallization solution of BTK protein (8 mg / ml in 20 mM Tris pH 8, 150 mM NaCl, 2 mM DTT) and an equal amount of a solution of 25-35% PEG MME 5K, 0.1 M MES pH 6-7, and 0.1-0.2 M AmSO4.
[0097] Crystals can be grown using sitting drop or hanging drop vapor diffusion techniques, such as, but not limited to, those described herein. Crystals can be grown in Corning® 384-well plates (available from Fisher Scientific), Greiner crystallization thin plates (available from Hampton Research, Aliso Viejo, Calif.), 96-well CrystalQuick™ standard round and flat bottom plates (available from Hampton Research, Aliso Viejo, Calif.), 24-well VDX plates (available from Hampton Research, Aliso Viejo, Calif.), and NeXtal EasyXtal 15-well plates (available from Molecular Dimensions, Maumee, Ohio). The volume of the reservoirs in the 384-well plates can be 50 μL. The volume of the reservoirs in the 96-well thin plates can be 100 μL, and for CrystalQuick™ plates, the volume of the reservoirs can vary between 70 and 100 μL. Crystals can also be grown in 72-well Terasaki plates using the microbatch method. Crystals can also be grown in 96-well Corning® plates (available from Hampton Research, Aliso Viejo, CA) with 50 μL reservoirs.
[0098] According to one embodiment, the invention provides a crystal having unit cell dimensions a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°, and space group p22121. Preferably, the crystal comprises a BTK-Compound I complex.
[0099] It will be readily apparent to one of ordinary skill in the art that the unit cell of the crystalline composition may deviate from the above lattice dimensions by up to ±1-2 Å in lattice length depending on deviations in the unit cell calculations or conformational changes in the protein.
[0100] The BTK protein may be produced by any known method, including synthetic methods such as solid phase synthesis, liquid phase synthesis, and combinations of solid and liquid phase synthesis, recombinant DNA methods including cDNA cloning, optionally in combination with site-directed mutagenesis, and / or natural product purification. In one embodiment, the protein is overexpressed in a baculovirus system.
[0101] Method for obtaining crystals of BTK or its complex The present invention also provides a method for obtaining crystals of a BTK protein, comprising the steps of: a) producing and purifying the BTK protein; b) combining a crystallization solution with the BTK protein to form a crystallizable composition; c) subjecting the crystallizable composition to conditions promoting crystallization to obtain crystals. The present invention relates to a method comprising the steps of:
[0102] The present invention also provides a method for obtaining crystals of a BTK protein complex, comprising the steps of: d) soaking the crystals in a buffer solution containing the compound of formula (I); The present invention relates to a method, further comprising:
[0103] In some embodiments, a method for obtaining crystals of a BTK protein complex comprises mixing a crystal of a compound of Formula (I) with a conformer. In some embodiments, the cofomer comprises saccharin, maleic acid, glycine, sulfacetamide, serine, ketoglutaric acid, orotic acid, maltol, urea, proline, nicotinic acid, L-lysine, isonicotinic acid, benzoic acid, nicotinamide, salicylic acid, isonicotinamide, 3-hydroxybenzoic acid, L-tartaric acid, 4-aminobenzoic acid, L-malic acid, succinic acid, citric acid, 2,5-dihydroxybenzoic acid, L-lactic acid, 2,4-dihydroxybenzoic acid, caffeine, sorbic acid, or L-glutamic acid. In some embodiments, ethanol is used to wet the mixture of the crystal of a compound of Formula (I) with a conformer. In some embodiments, the wet mixture of the crystals of the compound of formula (I) and the conformer is subjected to grinding to form a ground mixture of the crystals of the compound of formula (I) and the conformer. In some embodiments, the wet mixture of the crystals of the compound of formula (I) and the conformer is subjected to heating and cooling. In some embodiments, the ground mixture of the crystals of the compound of formula (I) and the conformer is air-dried to form a dry mixture of the crystals of the compound of formula (I) and the conformer. In some embodiments, the air-dried mixture of the crystals of the compound of formula (I) and the conformer is analyzed by XPRD. Some embodiments further include filtering the mixture of the crystals of the compound of formula (I) and the conformer prior to drying.
[0104] The present invention also provides a method for obtaining crystals of a BTK protein complex, comprising the steps of: a) producing and purifying the BTK protein; b) combining the BTK protein with a crystallization solution in the presence of a compound of formula (I) to form a crystallizable composition; c) subjecting the crystallizable composition to conditions promoting crystallization to obtain crystals. The present invention relates to a method comprising the steps of:
[0105] In certain embodiments, the method of producing crystals of BTK protein or complexes thereof includes the use of a crystallization-promoting apparatus, which may include, but is not limited to, a hanging drop apparatus, a sitting drop apparatus, a dialysis apparatus, or a microtube batch apparatus (U.S. Pat. Nos. 4,886,646, 5,096,676, 5,130,105, 5,221,410, and 5,400,741, Pav et al., Proteins: Structure, Function, and Genetics 20:98-102 (1994), which are incorporated herein by reference). Some applications of the hanging drop, sitting drop, and microbatch techniques (D'Arcy et al., J. Cryst. Growth 168:175-180 (1996) and Chayen, J. Appl. Cryst. 30:198-202 (1997)) generate crystals by vapor diffusion. Hanging and sitting drops containing the crystallizable composition are equilibrated in a reservoir with a higher or lower concentration of precipitant. As the drops approach equilibrium with the reservoir, crystals form due to saturation of the protein in solution.
[0106] Microseeding or seeding may be used to increase the size and quality of the crystals. In this case, microcrystals are milled to obtain a stock seed solution. This stock seed solution is serially diluted. Using a needle, glass rod, micropipette, microloop or hair, a small sample of each dilution solution is added to a set of equilibrated droplets containing a protein concentration equal to or less than that required to produce crystals in the absence of seeds. The aim is to eventually obtain a single seed crystal in the droplet that acts as a nucleus for crystal growth.
[0107] It will be readily apparent to one of skill in the art to modify the crystallization conditions disclosed above to identify other crystallization conditions that produce crystals of BTK protein or a BTK protein complex. Such modifications include, but are not limited to, adjusting the pH, protein concentration, and / or crystallization temperature, changing the identity or concentration of salts and / or precipitants used, using a different crystallization method, or introducing additives such as detergents (e.g., TWEEN 20 (monolaurate), LDAO, Brij 30 (4 lauryl ether)), sugars (e.g., glucose, maltose), organic compounds (e.g., dioxane, dimethylformamide), lanthanide ions, or polyionic compounds that promote crystallization. High-throughput crystallization studies may also be used to aid in the discovery or optimization of crystallization conditions.
[0108] BTK binding pocket As disclosed herein, Applicants have provided a three-dimensional X-ray structure of the BTK-Compound I complex. The atomic coordinates for the structure of the BTK-Compound I complex are shown in Table 2.
[0109] In order to use the structural coordinates generated for the BTK-Compound I complex or one of its binding pockets, it may be necessary to convert the structural coordinates, or a portion thereof, into a three-dimensional shape (i.e., a three-dimensional representation of these complexes or binding pockets). This is accomplished by using a computer and commercially available software that can generate a three-dimensional representation or structure of a molecule or molecular complex, or a portion thereof, from a set of structural coordinates. These three-dimensional representations may be displayed on a computer screen.
[0110] Binding pockets, also referred to as binding sites in the present invention, are of great value in fields such as drug discovery. The association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the binding pockets of receptors and enzymes. Such associations can occur in whole or in part in the binding pocket. Understanding such associations leads to the design of drugs that exhibit more favorable association with their target receptors or target enzymes and thus improved biological effects. This information is therefore useful for designing potential inhibitors of the binding pockets of biologically important targets. The binding pockets of the present invention are of importance for drug design.
[0111] The conformations of the BTK protein and other proteins at particular amino acid positions along the polypeptide backbone can be compared using well-known procedures for performing amino acid sequence alignments. Such sequence alignments make it possible to compare equivalent positions on these proteins. Such methods for performing sequence alignments include, but are not limited to, the "Bestfit" program and the CLUSTAL W alignment tool (Higgins et al., supra).
[0112] In one embodiment, the BTK binding pocket is comprised of the BTK kinase domain and includes amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to the structure of the BTK-Compound I complex in Table 2.
[0113] It will be readily apparent to one of skill in the art that the numbering of amino acid residues in homologs of human BTK may differ from that described for human BTK. Corresponding amino acids in BTK homologs are readily identified by visual inspection of the amino acid sequence or by using commercially available homology software programs. Homologs of BTK include BTK from other species, such as, for example, non-human primates, mice, and rats.
[0114] Those skilled in the art will appreciate that a set of structural coordinates for an enzyme or enzyme complex, or a portion thereof, is a set of relative points that define a three-dimensional shape. Thus, completely different sets of coordinates may define similar or identical shapes. Furthermore, small variations in individual coordinates have little effect on the overall shape. In the context of a binding pocket, such variations would not be expected to significantly alter the nature of the ligand that may associate with the binding pocket.
[0115] The above-mentioned variations in coordinates may arise due to mathematical manipulation of the structural coordinates of the BTK-Compound I complex. For example, the structural coordinates set forth in Table 2 may be subjected to crystallographic permutation of the structural coordinates, division of the structural coordinates, integer additions or subtractions to the set of structural coordinates, inversion of the structural coordinates, or any combination of the above.
[0116] Alternatively, modifications of the crystal structure by amino acid mutations, additions, substitutions and / or deletions, or other changes in any of the components that make up the crystal, may also cause variations in the structural coordinates. If such variations are within a certain mean square deviation compared to the original coordinates, the resulting three-dimensional shape is considered to be encompassed by the present invention. Thus, for example, a ligand bound to the kinase domain of BTK would be expected to also bind to another binding pocket whose structural coordinates define a shape that falls within the RMSD value.
[0117] To determine whether a molecule or binding pocket, or a portion thereof, is sufficiently similar to the binding pocket described above, various computer analyses may be required. Such analyses may be performed with well-known software applications, such as those described in ProFit (ProFit version 1.8, available from ACR Martin, University College London), Swiss-Pdb Viewer (Guex and Peitsch, Electrophoresis 18:2714-2723 (1997)), QUANTA's Molecular Similarity application (Accelrys, San Diego, Calif. (© 2001, 2002) and the accompanying user's guide, all of which are incorporated herein by reference.
[0118] These programs allow comparisons between different structures, different conformations of the same structure, and different parts of the same structure. The procedure used in QUANTA (Accelrys, San Diego, Calif. (Copyright 2001, 2002) and Swiss-Pdb Viewer (Guex and Peitsch, Electrophoresis 18:2714-2723 (1997)) to compare structures is divided into four steps: 1) loading the structures to be compared, 2) defining the equivalence of atoms in these structures, 3) performing fitting operations on the structures, and 4) analyzing the results.
[0119] The procedure used by ProFit to compare structures involves the following steps: The steps include 1) loading structures to be compared; 2) identifying selected residues of interest; 3) defining atomic equivalence at the selected residues; 4) performing fitting operations on the selected residues; and 5) analyzing the results.
[0120] Each structure in the comparison is identified by a name. Once one structure is identified as the target (i.e., fixed structure), all remaining structures become working structures (i.e., moving structures). Atom equivalence in QUANTA (Accelrys, San Diego, Calif. (© 2001, 2002) is defined by user input, so for the purposes of this invention, we define equivalent atoms as protein backbone atoms N, O, C, and Cα for all corresponding amino acid residues between the two structures being compared.
[0121] Corresponding amino acids may be identified by sequence alignment programs (e.g., the "Bestfit" program available from Genetics Computer Group, Inc.) using the local homology algorithm described by Smith and Waterman in Advances in Applied Mathematics 2:482 (1981), which is incorporated herein by reference. Proper amino acid sequence alignment requires that the aligned proteins share a minimum percentage of identical amino acids. In general, a first protein that is aligned with a second protein should share more than about 35% identical amino acids (Hanks et al., Science 241:42 (1988); J. Hanks and Quinn, Methods in Enzymology 200:38 (1991)). Identification of equivalent residues can also be aided by secondary structure alignment, e.g., alignment of α-helices, β-sheets in the structure. The program Swiss-Pdb Viewer (Guex and Peitsch, Electrophoresis 18:2714-2723 (1997)) uses an optimal algorithm based on secondary sequence alignment.
[0122] When using rigid fitting methods, a working structure is translated and rotated to obtain an optimal fit with the target structure. The fitting procedure uses an algorithm that calculates the optimal translation and rotation that can be applied to the moving structure such that the root mean square difference of the fit to a specified pair of equivalent atoms is an absolute minimum. The program reports this value, expressed in Angstroms. The Swiss-Pdb Viewer program (Guex and Peitsch, Electrophoresis 18:2714-2723 (1997)) sets an RMSD cutoff to eliminate equivalent atom pairs with high RMSD values. The RMSD cutoff value can be used to exclude equivalent atom pairs with extreme individual RMSD values. The program ProFit allows the user to specify the RMSD cutoff value.
[0123] For purposes of the present invention, any molecule, molecular complex, binding pocket, motif, domain thereof or portion thereof that is within the mean square deviation for the backbone atoms (N, Cα, C, O) when superimposed onto the relevant backbone atoms described by the structural coordinates listed in Table 2 is encompassed by the present invention.
[0124] One aspect of the invention provides a crystalline molecule comprising a protein defined by structural coordinates of a set of amino acid residues that are identical to the BTK amino acid residues according to Table 2, wherein the RMSD between the backbone atoms of the set of amino acid residues and the BTK amino acid residues is about 3.0 Å or less. In other embodiments, the RMSD between the set of amino acid residues and the backbone atoms of the BTK amino acid residues is about 2.0 Å or less, about 1.5 Å or less, about 1.1 Å or less, about 1.0 Å or less, about 0.9 Å or less, about 0.8 Å or less, about 0.7 Å or less, about 0.6 Å or less, or about 0.5 Å or less. Calculations of RMSD values were performed using the Swiss Pdb Viewer (Guex and Peitsch, Electrophoresis 18:2714-2723 (1997)).
[0125] In one embodiment, the invention provides a crystalline molecule comprising all or a portion of a binding pocket defined by a set of amino acid residues that include amino acid residues identical to human BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, wherein the RMSD of backbone atoms between the BTK amino acid residues and the identical amino acid residues is about 2.5 Å or less. In other embodiments, the RMSD is less than or equal to about 2.4 Å, about 2.2 Å, about 2.0 Å, about 1.8 Å, about 1.6 Å, about 1.4 Å, about 1.2 Å, about 1.0 Å, about 0.8 Å, about 0.5 Å, about 0.3 Å, or about 0.2 Å. In other embodiments, the binding pocket is defined by a set of amino acid residues that includes at least 4, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues that are identical to BTK amino acid residues.
[0126] Method for preparing BTK crystalline compositions The BTK protein may be produced by any known method, including synthetic methods such as solid phase synthesis, liquid phase synthesis, and combinations of solid and liquid phase synthesis, recombinant DNA methods, including cDNA cloning, optionally in combination with site-directed mutagenesis, and / or natural product purification. In one embodiment, the protein is overexpressed in a baculovirus system or an E. coli system. In another embodiment, the protein is overexpressed in a baculovirus system.
[0127] The present invention also provides methods for producing crystals of BTK protein in the presence or absence of a chemical, such as Compound 1. Such methods include the steps of a) producing and purifying BTK protein, b) combining the BTK protein or a homolog thereof with a crystallization solution in the presence or absence of a chemical to produce a crystallizable composition, and c) subjecting the crystallizable composition to conditions that promote crystallization.
[0128] The crystallization solution may include, but is not limited to, about 10%-35% v / v polyethylene glycol (PEG), 100-300 mM ammonium sulfate, and a buffer that maintains a pH of about 4.0 to 8.0. In one embodiment, the crystallization solution includes 31% PEG MME 5K, 100 mM 2-(N-morpholino)ethanesulfonic acid (MES) at pH 6.75, and 200 mM ammonium sulfate.
[0129] In one embodiment, the crystallizable composition comprises BTK protein in the presence or absence of a chemical (e.g., Compound I). In another embodiment, the crystallizable composition comprises BTK protein and a chemical. In one embodiment, the crystallizable composition further comprises a precipitant, about 10-30% v / v polyethylene glycol (PEG), 100-300 mM ammonium sulfate, a buffer maintaining a pH of about 4.0-8.0, and optionally, about 1-20 mM of a reducing agent, such as dithiothreitol (DTT). The BTK protein may be further modified to include a post-translational modification. The BTK protein or complex is preferably 85-100% pure prior to forming the composition. More preferably, the BTK protein or complex is 90-100% pure. More preferably, the BTK protein or complex is 95-100% pure.
[0130] It will be readily apparent to one of skill in the art to modify the crystallization conditions disclosed above to identify other crystallization conditions that will produce crystals of the BTK protein or its homologs in the presence or absence of a ligand. Such modifications include, but are not limited to, adjusting the pH, protein concentration, and / or crystallization temperature, changing the identity or concentration of salts and / or precipitants used, using a different crystallization method, or introducing additives such as detergents (e.g., TWEEN® 20 (monolaurate), LDOA, BRIJ30® (4 lauryl ether)), sugars (e.g., glucose, maltose), organic compounds (e.g., dioxane, dimethylformamide), lanthanide ions, or polyionic compounds that promote crystallization. High-throughput crystallization studies may also be used to aid in the discovery or optimization of crystallization conditions.
[0131] Methods for identifying and / or designing candidate inhibitors of BTK A further aspect of the present invention is a method for identifying and / or designing candidate inhibitors using human BTK crystals comprising the human BTK protein, the method comprising: a) preparing a crystalline composition of BTK and Compound I; b) soaking another candidate inhibitor into the crystalline composition and displacing the compound of Formula (I) (the parent ligand) to form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) using the structural coordinates obtained in step c) to design and / or identify a candidate inhibitor; and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0132] In one embodiment, a molecular complex comprising BTK with a ligand. In one embodiment, a molecular complex comprising SEQ ID NO:3 and a ligand, forming a crystalline composition characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°, the crystalline solution being buffered to pH 5.0-7.0 and comprising 10-15% PEG and 50 mM ammonium sulfate. In one embodiment, the molecular complex comprises SEQ ID NO:3 and a ligand, the ligand being a compound of formula (I):
[0133] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0134] In some embodiments, the molecular complex of BTK with Compound I bound to the binding site provides important structural information for the development of novel BTK inhibitors. The present invention includes a crystalline composition of a molecular complex comprising SEQ ID NO:3 and Compound I, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°.
[0135] Those skilled in the art will recognize that modifications at the C-terminus and N-terminus, as well as substitutions including mutations, glycosylations, acylations and methylations of some amino acid residues are possible, all of which are considered equivalents within the scope of the invention.
[0136] In one embodiment, a method for identifying candidate inhibitors of BTK comprises generating a three-dimensional structure of a BTK binding site on a computer, the three-dimensional structure coordinates having unit cell parameters and space group parameters of a crystalline composition comprising SEQ ID NO:3 and a ligand, the ligand being a compound of Formula (I)
[0137] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the crystalline composition is characterized by space group p22121 with unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°, and using the three-dimensional structure to design or select candidate inhibitors; and contacting the candidate inhibitors with human BTK and measuring the ability of the candidate inhibitors to bind to BTK.
[0138] In another aspect, a method of identifying candidate inhibitors of BTK includes generating a three-dimensional structure of a BTK binding site on a computer, the three-dimensional structural coordinates having unit cell and space group parameters of a crystalline composition comprising SEQ ID NO:3 and a ligand, the crystalline composition being characterized by space group p22121 with unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; using the three-dimensional structure to design or select candidate inhibitors, wherein the candidate inhibitor forms a direct covalent bond with Cys481 and the candidate inhibitor forms hydrogen bonds with Lys430, Met477, Asp539, or any combination thereof; contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0139] Computational methods for identifying candidate inhibitors of BTK According to another aspect, the invention provides a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, the data defining said molecule or molecular complex. In one embodiment, the data defines said binding pocket by including structural coordinates of amino acid residues according to Table 2. To use the structural coordinates generated for BTK or a BTK kinase domain, it may be necessary to convert them into a three-dimensional shape or extract three-dimensional structural information therefrom. This is accomplished by use of commercially or publicly available software capable of generating a three-dimensional structure or representation of a molecule or portion thereof from a set of structural coordinates. In one embodiment, the three-dimensional structure or representation may be displayed graphically.
[0140] Thus, according to another embodiment, the invention provides a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, In one embodiment, a machine programmed with instructions for using the data is capable of generating a three-dimensional structure or representation of any of the molecules described herein, or molecular complexes or binding pockets thereof.
[0141] The present invention also provides (a) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, the data defining any one of the molecules or molecular complexes described above; (b) a working memory for storing instructions for processing the machine-readable data; and (c) a central processing unit (CPU) coupled to the working memory and the machine-readable data storage medium for processing the machine-readable data, and means for generating three-dimensional structural information of the molecule or molecular complex; (d) providing a computer coupled to the central processing unit and including output hardware for outputting the three-dimensional structural information of the molecule or molecular complex, or information generated using the three-dimensional structural information of the molecule or molecular complex.
[0142] In one aspect, the data defines a binding pocket of the molecule or molecular complex.
[0143] The generation of the three-dimensional data may be obtained by an instruction or set of instructions, such as a computer program or commands, for generating a three-dimensional structure or graphical representation from structural coordinates, or by subtracting distances between atoms, calculating the chemical energy of a BTK molecule or molecular complex, or calculating or minimizing the energy of association of a BTK molecule or its molecular complex to a chemical entity, such as Compound I. The graphical representation may be generated or displayed by commercially available software programs. Examples of software programs include, but are not limited to, QUANTA (Accelrys, Inc., San Diego, Calif. (Copyright 2001, 2002), O (Jones et al., Acta Crystallogr. A 47:110-119 (1991)), and RIBBON (Carson, J. Appl. Crystallogr. 24:958-961 (1991)), which are incorporated herein by reference. Certain software programs can incorporate into this representation physicochemical attributes known from the chemical composition of the molecule, such as residue charge, hydrophobicity, torsional and rotational degrees of freedom of residues or segments, etc. Examples of software programs for calculating chemical energy are described in the section on rational drug design.
[0144] Information regarding the binding pocket or information generated using the binding pocket can be output via a display terminal, touch screen, facsimile machine, modem, CD-ROM, printer, CD or DVD recorder, ZIP™ or JAZ™ drive, or disk drive. The information can be in graphical or alphanumeric format.
[0145] In one embodiment, the computer is executing instructions, such as a computer program for generating three-dimensional structures or docking. In another embodiment, the computer further includes a commercially available software program for displaying information as a graphical representation. Examples of software programs include, but are not limited to, QUANTA (Accelrys, San Diego, Calif. (Copyright) 2001, 2002), O (Jones et al., Acta Crystallogr. A 47:110-119 (1991)), and RIBBON (Carson, J. Appl. Crystallogr. 24:958-961 (1991)), all of which are incorporated herein by reference.
[0146] Thus, according to the invention, data capable of generating a three-dimensional structure or a three-dimensional representation of said molecule or molecular complex, or of their binding pocket, can be stored in a machine-readable storage medium capable of displaying structural information or a graphical three-dimensional representation of the structure. In one embodiment, the means for generating three-dimensional information is obtained by means for generating a three-dimensional structural representation of the binding pocket of the molecule or molecular complex, or of the protein.
[0147] Another aspect of the invention is a method of identifying candidate inhibitors of BTK, the method comprising: generating a three-dimensional structure of a binding site of BTK on a computer, the three-dimensional structural coordinates having the coordinates and space group parameters of a unit cell of a crystalline composition of the invention; using the three-dimensional structure to design or select candidate inhibitors; and contacting the candidate inhibitors with human BTK and measuring the ability of the candidate inhibitors to bind to BTK.
[0148] The invention disclosed herein will be useful for identifying BTK inhibitors and studying the role of BTK in cell signaling. In order to use the structural coordinates generated for BTK or a BTK complex, it is often necessary to convert the structural coordinates into a three-dimensional shape. This is accomplished by using commercially available software that can generate a three-dimensional graphical representation of a molecule or a portion thereof from a set of structural coordinates.
[0149] Binding pockets, also referred to as binding sites in the present invention, are of great value in fields such as drug discovery. The association of natural ligands or substrates with the binding pockets of their corresponding receptors or enzymes is the basis of many biological mechanisms of action. Similarly, many drugs exert their biological effects through association with the binding pockets of receptors and enzymes. Such associations can occur in whole or in part in the binding pocket. Understanding such associations leads to the design of drugs that exhibit more favorable association with their target receptors or enzymes and thus improved biological effects. This information is therefore useful for designing potential inhibitors of the binding pockets of biologically important targets.
[0150] In one embodiment, a portion of the binding pocket is at least two amino acid residues, preferably amino acid residues 389 to 659 of BTK, which correspond to the kinase domain of BTK. In another embodiment, the binding pocket is represented by SEQ ID NO:3.
[0151] Another embodiment is a method of identifying candidate inhibitors of BTK comprising: generating on a computer a three-dimensional structure of a BTK binding site, the three-dimensional structural coordinates having unit cell and space group parameters of a crystalline composition comprising SEQ ID NO:3 and a ligand, the crystalline composition being characterized by space group p22121 with unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; designing or selecting candidate inhibitors using the three-dimensional structure, wherein the candidate inhibitor forms a direct covalent bond with Cys481, the candidate inhibitor forms a hydrogen bond with Lys430, the candidate inhibitor forms a hydrogen bond with Met477, and the candidate inhibitor forms a hydrogen bond with Asp539; contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0152] Another embodiment is a method of identifying candidate inhibitors of BTK comprising: generating on a computer a three-dimensional structure of a BTK binding site, the three-dimensional structural coordinates having unit cell and space group parameters of a crystalline composition comprising SEQ ID NO:3 and a ligand, the crystalline composition being characterized by space group p22121 with unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; designing or selecting candidate inhibitors using the three-dimensional structure, wherein the candidate inhibitor forms a direct covalent bond with Cys481, the candidate inhibitor forms a hydrogen bond with Lys430, the candidate inhibitor forms a hydrogen bond with Met477, and the candidate inhibitor forms a hydrogen bond with Asp539; contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0153] Another aspect is a method of identifying and / or designing candidate inhibitors using human BTK crystals comprising the human BTK protein, comprising: a) preparing a crystalline composition comprising SEQ ID NO:3 and a ligand, such as Compound I, wherein the crystalline composition is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°, and wherein the ligand is a compound of formula (I)
[0154] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof; b) soaking another candidate inhibitor in the crystalline composition and displacing the compound of formula (I) (the original ligand) to form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) designing or identifying a candidate inhibitor using the structural coordinates obtained in step b); and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0155] The structural coordinates of BTK, or three-dimensional graphical representations generated from these coordinates, may be used in conjunction with a computer for a variety of purposes, including drug discovery.
[0156] For example, a structure encoded by the data may be evaluated by a computer for its ability to associate with a chemical entity. Chemical entities that associate with BTK may inhibit BTK or its homologs and are potential drug candidates. Alternatively, a structure encoded by the data may be displayed in a graphical three-dimensional representation on a computer screen, allowing visual inspection of the structure and its association with a chemical entity.
[0157] In another aspect, the present invention provides a method for designing, selecting and / or optimizing a chemical entity that binds to all or a portion of a molecule or molecular complex, the method comprising the steps of: (a) providing structural coordinates of the molecule or molecular complex on a computer comprising means for generating three-dimensional structural information of all or a portion of the molecule or molecular complex from the structural coordinates; (b) designing, selecting and / or optimizing the chemical entity by using means for performing fitting operations between the chemical entity and the three-dimensional structural information of all or a portion of the molecule or molecular complex; and (c) contacting a candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0158] In another aspect, the method comprises the steps of: (a) constructing a computer model of the binding pocket of BTK; (b) selecting a chemical entity to be evaluated by de novo ligand design or by modifying a known agonist or inhibitor, or portion thereof; (c) performing a fitting operation between the computer model of the chemical entity to be evaluated and the binding pocket using computational means to obtain an energy-minimized configuration of the chemical entity within the binding pocket; and (d) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0159] The three-dimensional structural information in step (a) is used to generate a three-dimensional structure or graphical representation, subtract distances between atoms, calculate the chemical energy of the BTK molecule, molecular complex or homologues thereof, or calculate or minimize the energy of association of the BTK molecule, molecular complex or homologues thereof to a chemical entity. The graphic representation can be generated by instructions, such as computer programs or commands, that can display the graphic representation. These types of computer programs are known in the art. The graphic representation can be generated or displayed by commercially available software programs. Examples of software programs include, but are not limited to, 1. Coot, (Features and Development of Coot, Acta Crystallographica Section D-Biological Crystallography, 2010, vol 66, pp486-501, by Paul Emsley and Bernhard Lohkamp and William G. Scott and Kevin Cowtan), 2. PyMOL (The PyMOL Molecular Graphics System, Schrodinger), and 3. MOE (Molecular Operating Environment), Molecular Operating Environment (MOE), 2019.01, Chemical Computing Group. Certain software programs can incorporate into the representation physicochemical attributes known from the chemical composition of the molecule, such as residue charge, hydrophobicity, torsional and rotational degrees of freedom of residues or segments.
[0160] The design of compounds that bind to or inhibit the BTK binding pocket in accordance with the present invention generally involves taking into consideration two factors. First, the chemical entity must be able to physically and structurally associate with part or all of the BTK binding pocket. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions.
[0161] Second, the chemical entity must be able to adopt a conformation that allows it to directly associate with the BTK binding pocket. Although certain portions of the chemical entity are indirectly involved through one or more water molecules, those portions of the chemical entity may still affect the overall binding of the chemical entity to BTK. This in turn may have a large effect on efficacy. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity in relation to all or part of the binding pocket.
[0162] A multiple alignment program is used to compare the structure of each BTK to the structures of other members of the protein family. To compare the structures, first a sequence alignment between the protein sequences is performed. A putative core is then constructed by superimposing a set of corresponding structures within the protein family. Residues with high spatial variance are then truncated and the core alignment is iteratively refined. The amino acids that make up the final core structure have low structural variance and the same local and global conformations compared to the corresponding residues within the protein family.
[0163] In one embodiment, the binding pocket comprises SEQ ID NO: 3. In another embodiment, the binding pocket comprises amino acid residues 389-659 of BTK, which represents the kinase domain of BTK.
[0164] Those skilled in the art will understand that a set of structural coordinates for a molecule or molecular complex, or a portion thereof, is a set of relative points that define a three-dimensional shape. Thus, completely different sets of coordinates may define similar or identical shapes. Furthermore, small variations in individual coordinates will have little effect on the overall shape. In the context of a binding pocket, such variations would not be expected to significantly alter the nature of the ligand that may associate with the binding pocket.
[0165] The above-mentioned variations in coordinates may result from mathematical manipulation of the structural coordinates of BTK. For example, the structural coordinates may be manipulated by crystallographic permutation of the structural coordinates, division of the structural coordinates, integer additions or subtractions to a set of structural coordinates, inversion of the structural coordinates, or any combination of the above.
[0166] Alternatively, modifications of the crystal structure by amino acid mutations, additions, substitutions and / or deletions, or other changes in any of the components that make up the crystal, may also cause variations in the structural coordinates. If such variations are within a certain mean square deviation compared to the original coordinates, the resulting three-dimensional shape is considered to be encompassed by the present invention. Thus, for example, a ligand that binds to a binding pocket of BTK would also be expected to bind to another binding pocket whose structural coordinates define a shape that falls within an acceptable mean square deviation.
[0167] A variety of computational analyses may be required to determine whether a binding pocket, binding motif, binding domain, or portion thereof of a molecule or molecular complex is sufficiently similar to a binding pocket, binding motif, binding domain, or portion thereof of BTK, such as the kinase domain of BTK. Such analyses may be performed using well-known software applications, such as those described in ProFit (ACR Martin, SciTech Software, Inc., ProFit version 1.8, University College London, www.bioinf.org.uk / software), Swiss-Pdb Viewer (Guex et al., Electrophoresis, 18, pp. 2714-2723 (1997)), QUANTA's Molecular Similarity application (Molecular Simulations, Inc., San Diego, Calif. (© 1998, 2000) and the accompanying user's guide, which are incorporated herein by reference.
[0168] These programs allow comparisons between different structures, different conformations of the same structure, and different parts of the same structure. The procedure used by QUANTA (Molecular Simulations, San Diego, Calif. (Copyright 1998, 2000) and the Swiss-Pdb Viewer to compare structures is divided into four steps: 1) loading the structures to be compared, 2) defining the equivalence of atoms in these structures, 3) performing fitting operations on the structures, and 4) analyzing the results.
[0169] The procedure used by ProFit to compare structures involves the following steps: The steps include 1) loading structures to be compared; 2) identifying selected residues of interest; 3) defining atomic equivalence at the selected residues; 4) performing fitting operations on the selected residues; and 5) analyzing the results.
[0170] Each structure in the comparison is identified by a name. Once one structure is identified as the target (i.e., fixed structure), all remaining structures become working structures (i.e., moving structures). Atom equivalence within the program is defined by user input, so for the purposes of this invention, we define equivalent atoms as protein backbone atoms (N, Ca, C, and O) for BTK amino acids and corresponding amino acids in the compared structures.
[0171] Corresponding amino acids may be identified by sequence alignment programs (e.g., the "Bestfit" program available from Genetics Computer Group, Inc.) using the local homology algorithm described by Smith and Waterman in Advances in Applied Mathematics 2, 482 (1981), which is incorporated herein by reference. Proper amino acid sequence alignment requires that the aligned proteins share a minimum percentage of identical amino acids. In general, a first protein that is aligned with a second protein should share more than about 35% identical amino acids (Hanks et al., Science, 241, 42 (1988); J. Hanks and Quinn, Methods in Enzymology, 200, 38 (1991)). Identification of equivalent residues can also be aided by secondary structure alignment, e.g., alignment of α-helices, β-sheets in the structure. The program Swiss-Pdb Viewer has a unique optimization algorithm based on secondary sequence alignment.
[0172] When using rigid fitting methods, a working structure is translated and rotated to obtain an optimal fit with the target structure. The fitting procedure uses an algorithm that calculates the optimal translation and rotation that can be applied to the moving structure such that the root mean square difference of the fit to a specified pair of equivalent atoms is an absolute minimum. The program reports this value, expressed in Angstroms. In the Swiss-Pdb Viewer program, an RMSD cutoff is set to eliminate equivalent atom pairs with high RMSD values. The RMSD cutoff value can be used to exclude equivalent atom pairs with extreme individual RMSD values. The program ProFit allows the user to specify the RMSD cutoff value.
[0173] For purposes of the present invention, any molecule, molecular complex, binding pocket, motif, domain thereof or portion thereof that is within the mean square deviation for a backbone atom (N, Cα, C, O) when superimposed onto the relevant backbone atoms described by the structural coordinates is encompassed by the present invention.
[0174] Thus, one aspect of the invention provides a molecule or molecular complex comprising all or a portion of a BTK binding pocket defined by the structural coordinates of the set of amino acid residues corresponding to BTK amino acid residues 389-659, wherein the root mean square deviation of backbone atoms between the amino acids of the molecule or molecular complex and the BTK amino acids is about 3.0 Å or less. In one embodiment, the RMSD is about 2.0 Å or less. In one embodiment, the RMSD is about 1.0 Å or less. In one embodiment, the RMSD is about 0.8 Å or less. In one embodiment, the RMSD is about 0.5 Å or less. In one embodiment, the RMSD is about 0.3 Å or less. In one embodiment, the RMSD is about 0.2 Å or less.
[0175] Thus, one aspect of the invention provides a molecule or molecular complex comprising all or a portion of a BTK binding pocket defined by structural coordinates of a set of amino acid residues corresponding to SEQ ID NO:3, wherein the root mean square deviation of backbone atoms between the amino acids of the molecule or molecular complex and the BTK amino acids is about 3.0 Å or less. In one embodiment, the RMSD is about 2.0 Å or less. In one embodiment, the RMSD is about 1.0 Å or less. In one embodiment, the RMSD is about 0.8 Å or less. In one embodiment, the RMSD is about 0.5 Å or less. In one embodiment, the RMSD is about 0.3 Å or less. In one embodiment, the RMSD is about 0.2 Å or less.
[0176] Rational Drug Design The structural coordinates of BTK, or three-dimensional graphical representations generated from these coordinates, may be used in conjunction with a computer for a variety of purposes, including drug discovery.
[0177] For example, a structure encoded by the data may be evaluated by a computer for its ability to associate with a chemical entity. Chemical entities that associate with BTK may inhibit BTK and are potential drug candidates. Alternatively, a structure encoded by the data may be displayed in a graphical three-dimensional representation on a computer screen, allowing visual inspection of the structure and its association with a chemical entity.
[0178] Thus, according to another embodiment, the present invention provides a method for designing, selecting and / or optimizing a chemical entity that binds to all or part of a molecule or molecular complex, comprising the steps of: (a) providing structural coordinates of a molecule or molecular complex on a computer that comprises means for generating three-dimensional structural information of all or a portion of the molecule or molecular complex from the structural coordinates; (b) designing, selecting and / or optimizing chemical compounds by using a means for performing fitting operations between the chemical compounds and three-dimensional structural information of all or part of a molecule or molecular complex; The present invention provides a method comprising:
[0179] In one embodiment, the method is for designing, selecting and / or optimizing a chemical entity that binds to a binding pocket of a molecule or molecular complex. In one embodiment, the method further comprises the steps of: (c) generating a crystal of a molecule or molecular complex comprising BTK; (d) determining the three-dimensional structural coordinates of the molecule or molecular complex by X-ray diffraction of the crystal; and (e) identifying all or a portion of the binding pocket Further includes.
[0180] The three-dimensional structural information in step (a) is used to generate a three-dimensional structure or graphical representation, subtract distances between atoms, calculate the chemical energy of the BTK molecule, molecular complex or homologues thereof, or calculate or minimize the energy of association of the BTK molecule, molecular complex or homologues thereof to a chemical entity. The graphical representation can be generated by instructions, such as computer programs or commands, that can display the graphical representation. These types of computer programs are known in the art. The graphical representation can be generated or displayed by commercially available software programs. Examples of software programs include, but are not limited to, QUANTA (Accelrys, Inc., (Copyright) 2001, 2002), O (Jones et al., Acta Crystallogr., 447, pp. 110-119 (1991)), and RIBBONS (Carson, J. Appl. Crystallogr., 24, pp. 9589-961 (1991)), which are incorporated herein by reference. Certain software programs can incorporate into the representation physicochemical attributes known from the chemical composition of the molecule, such as residue charge, hydrophobicity, torsional and rotational degrees of freedom of residues or segments. Examples of software programs for calculating chemical energy are described below.
[0181] Thus, according to another embodiment, the present invention provides a method for assessing the likelihood that a chemical entity will associate with all or a portion of a molecule or molecular complex as described above in various embodiments.
[0182] The method includes the steps of (a) using a computational means to perform a fitting operation between a chemical entity and all or a portion of the molecule or molecular complex described above, (b) analyzing the results of the fitting operation to quantify the association between the chemical entity and all or a portion of the molecule or molecular complex, and, optionally, (c) outputting the quantified association to a suitable output hardware, such as a CRT display terminal, a CD recorder or DVD recorder, a ZIP™ drive or a JAZ™ drive, a disk drive, or other machine-readable data storage device, as described above. The method may further include, prior to step (a), generating a three-dimensional structure, a graphical representation thereof, or both of all or a portion of the molecule or molecular complex. In one embodiment, the method is for evaluating the ability of a chemical entity to associate with all or a portion of a binding pocket of a molecule or molecular complex.
[0183] In another embodiment, the present invention provides a method for screening a plurality of chemical entities that associate with a binding pocket with a deformation energy of binding less than -7 kcal / mol, comprising: (a) using computational means to perform a fitting operation between one of the chemical entities from the plurality of chemical entities and the binding pocket using the structural coordinates; (b) quantifying the deformation energy of binding between the chemical entity and the binding pocket; (c) repeating steps (a) and (b) for each remaining chemical; and (d) - outputting to suitable output hardware the set of chemical entities that associate with the binding pocket with a deformation energy of binding of less than 7 kcal / mol.
[0184] In another embodiment, the method comprises: (a) constructing a computer model of the binding pocket of a molecule or molecular complex; (b) selecting chemicals to be evaluated by a method selected from the group consisting of chemical construction, selecting chemicals from small molecule databases, de novo ligand design of chemicals, and modifying known agonists or inhibitors of BTK protein or homologs thereof, or portions thereof; (c) performing a fitting procedure using computational means between a computer model of the chemical entity to be evaluated and the binding pocket to obtain an energy-minimized configuration of the chemical entity within the binding pocket; (d) evaluating the results of the fitting operation to quantify the association between the chemical entity and the binding pocket model, thereby evaluating the ability of the chemical entity to associate with the binding pocket; Includes.
[0185] In another embodiment, the invention provides a method of using a computer to evaluate the ability of a chemical entity to bind to all or a portion of a molecule or molecular complex, the method comprising: a machine-readable data storage medium comprising a data storage material encoded with structural coordinates defining a binding pocket; and means for generating a three-dimensional graphical representation of the binding pocket, the method comprising: (a) placing a first chemical entity within all or a portion of the binding pocket using a graphical three-dimensional representation of the chemical entity and the structure of the binding pocket; (b) performing a fitting operation between the chemical entity and the binding pocket by using a computational means; (c) analyzing the results of the fitting procedure to quantify the association between the chemical entity and all or a portion of the binding pocket; (d) outputting the quantified association to suitable output hardware; Includes.
[0186] The above method is (e) repeating steps (a) through (d) using a second chemical; and (f) selecting at least one of the first chemical or the second chemical that associates with all or a portion of the binding pocket based on the quantified association of the first chemical or the second chemical; It may further include.
[0187] Alternatively, the structural coordinates of the BTK binding pocket may be utilized in a method for identifying agonists or antagonists of molecules that contain the binding pocket of BTK. (a) using the three-dimensional structure of the molecule or molecular complex to design or select a chemical compound; (b) contacting a chemical with the molecules and molecular complexes; (c) monitoring the activity of the molecule or molecular complex; (d) classifying the chemical as an agonist or antagonist based on the effect of the chemical on the activity of the molecule or molecular complex. Includes.
[0188] In one embodiment, step (a) uses a three-dimensional structure of the binding pocket of the molecule or molecular complex, hi another embodiment, the three-dimensional structure is displayed as a graphical representation.
[0189] In another embodiment, the method comprises: (a) constructing a computer model of the binding pocket of a molecule or molecular complex; (b) selecting chemicals to be evaluated by a method selected from the group consisting of chemical construction, selecting chemicals from small molecule databases, de novo ligand design of chemicals, and modifying known agonists or inhibitors of BTK protein or homologs thereof, or portions thereof; (c) performing a fitting procedure using computational means between a computer model of the chemical entity to be evaluated and the binding pocket to obtain an energy-minimized configuration of the chemical entity within the binding pocket; (d) evaluating the results of the fitting operation to quantify the association between the chemical entity and the binding pocket model, thereby evaluating the ability of the chemical entity to associate with the binding pocket; (e) synthesizing a chemical compound; (f) contacting a chemical compound with the molecule or molecular complex to determine the ability of the compound to activate or inhibit the precursor molecule; Includes.
[0190] In one embodiment, the invention provides a method for designing a compound or complex that associates with all or a portion of a binding pocket, comprising the steps of: (a) providing structural coordinates of a binding pocket or protein on a computer comprising means for generating three-dimensional structural information from the structural coordinates; (b) performing a computer-assisted fitting procedure to associate a first chemical entity with all or a portion of the binding pocket; (c) performing a fitting operation to associate at least a second chemical entity with all or a portion of the binding pocket; (d) quantifying the association between the first and second chemical entities and all or a portion of the binding pocket; (e) repeating steps (b) through (d) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (f) optionally visually inspecting, on a computer screen using a three-dimensional graphical representation of the binding pocket and the first and second chemicals, the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket; (g) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that associates with all or a portion of the binding pocket.
[0191] The present invention enables, for the first time, the use of molecular design techniques to identify, select and design chemical compounds, including inhibitor compounds, capable of binding to BTK or BTK-like binding pockets, motifs and domains.
[0192] Applicants' elucidation of the binding pocket on BTK provides the information necessary to design new chemical entities and compounds that can interact, in whole or in part, with BTK substrates or BTK-like substrates.
[0193] Throughout this section, when discussing the ability of a chemical entity to bind to, associate with, or inhibit the BTK binding pocket, reference is made to the characteristics of the entity alone. Assays for determining whether a compound binds to BTK are known in the art and are exemplified below.
[0194] The design of compounds that bind to or inhibit the BTK binding pocket in accordance with the present invention generally involves taking into consideration two factors. First, the chemical entity must be able to physically and structurally associate with part or all of the BTK binding pocket. Non-covalent molecular interactions important in this association include hydrogen bonding, van der Waals interactions, hydrophobic interactions, and electrostatic interactions.
[0195] Second, the chemical entity must be able to adopt a conformation that allows it to directly associate with the BTK binding pocket. Although certain portions of the chemical entity are not directly involved in these associations, such portions of the chemical entity can still affect the overall conformation of the molecule. This in turn can have a significant effect on efficacy. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity relative to all or a portion of the binding pocket, or the spacing between functional groups of the chemical entity, including several chemical entities that directly interact with the BTK binding pocket or a BTK-like binding pocket.
[0196] By using computer modeling techniques, the potential inhibitory or binding effect of a chemical compound on the BTK binding pocket may be analyzed prior to its actual synthesis and testing. If the theoretical structure of a particular substance suggests that the interaction and association between the substance and the BTK binding pocket is insufficient, testing of the substance may be unnecessary. However, if computer modeling indicates a strong interaction, the molecule may be synthesized and its ability to bind to the BTK binding pocket may be tested. This may be accomplished by testing the molecule's ability to inhibit BTK. In this way, synthesis of compounds that will not work may be avoided.
[0197] Potential inhibitors of the BTK binding pocket can be computationally evaluated by a series of steps to screen and select chemical entities or fragments for their ability to associate with the BTK binding pocket.
[0198] One of skill in the art may screen chemical entities or fragments for their ability to associate with the BTK binding pocket using one of several methods. This process may begin with visual inspection of the BTK binding pocket on a computer screen, for example, based on BTK structural coordinates or other coordinates that define a similar shape generated from a machine-readable storage medium. Selected fragments or chemical entities may then be positioned or docked in various orientations within the above-defined binding pocket. Docking may be accomplished using software such as QUANTA (Molecular Simulations, San Diego, Calif., (Copyright) 1998, 2000) and Sybyl (Tripos Associates, St. Louis, Mo.), followed by energy minimization and molecular dynamics using standard molecular mechanics force fields such as CHARMM and AMBER.
[0199] The process of fragment or chemical selection may be assisted by dedicated computer programs. These include: 1. GRID (P. J. Goodford, "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biological Important Macromolecules", J. Med. Chem., 28, pp. 849-857 (1985)). GRID is available from Oxford University, Oxford, UK. 2. MCSS (A. Miranker et al., "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method." Proteins: Structure, Function and Genetics, 11, pp. 29-34 (1991)). MCSS is available from Molecular Simulations, Inc., San Diego, Calif. 3. AUTODOCK (DS Goodsell et al., "Automated Docking of Substrates to Proteins by Simulated Annealing", Proteins: Structure, Function, and Genetics, 8, pp. 195-202 (1990)). AUTODOCK is available from Scripps Research Institute, La Jolla, Calif. 4. DOCK (ID Kuntz et al., "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol., 161, pp. 269-288 (1982)). DOCK is available from the University of California, San Francisco, California.
[0200] After appropriate chemical entities, entities or fragments are selected, they may be assembled into a single compound or complex. Prior to assembly, the fragments may be visually inspected in relation to one another on a three-dimensional image displayed on a computer screen in relation to the structural coordinates of BTK. This may be followed by manual model building using software such as QUANTA (Molecular Simulations, San Diego, Calif. (Copyright 1998, 2000) or Sybyl (Tripos Associates, St. Louis, Mo.).
[0201] Useful programs to assist one of skill in the art in linking individual chemical entities or fragments include the following: 1. CAVEAT (PA Bartlett et al., "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules", Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc., 78, pp. 182-196 (1989); G. Lauri and PA Bartlett, "CAVEAT: a Program to Facilitate the Design of Organic Molecules", J. Comput. Aided mol. Des., 8, pp. 51-66 (1994)). CAVEAT is available from the University of California, Berkeley, California. 2. 3D database systems such as ISIS (MDL Information Systems, San Leandro, Calif.) This area is reviewed in "3D Database Searching in Drug Design" by YC Martin, J. Med. Chem. 35, pp. 2145-2154 (1992). 3. HOOK (MB Eisen et al., "HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site", Proteins: Struct., Funct., Genet., 19, pp. 199-221 (1994)). HOOK is available from Molecular Simulations, Inc., San Diego, Calif.
[0202] Instead of proceeding to construct an inhibitor of the BTK binding pocket stepwise, one fragment or chemical entity at a time, as described above, an inhibitory compound or other BTK-binding compound may be designed in its entirety, or "de novo," with an empty binding pocket, or optionally with the inclusion of a portion of one or more known inhibitors. There are a number of methods for de novo ligand design, including the following: 1. LUDI (H.-J. Bohm, "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", J. Comp. Aid. Molec. Design, 6, pp. 61-78 (1992)). LUDI is available from Molecular Simulations, Inc., San Diego, Calif. 2. LEGEND (Y. Nishibata et al., Tetrahedron, 47, p. 8985 (1991)). LEGEND is available from Molecular Simulations, Inc., San Diego, California. 3. LeapFrog (available from Tripos Associates, St. Louis, Missouri). 4. SPROUT (V. Gillet et al., "SPROUT: A Program for Structure Generation"), J. Comput. Aided Mol. Design, 7, pp. 127-153 (1993)). SPROUT is available from the University of Leeds, UK.
[0203] Other molecular modeling techniques may also be used in accordance with the present invention (see, for example, "Molecular Modeling Software and Methods for Medicinal Chemistry" by Cohen et al., J. Med. Chem., 33, pp. 883-894 (1990), as well as "The Use of Structural Information in Drug Design" by MA Avia and MAMurcko, Current Opinions in Structural Biology, 2, pp. 202-210 (1992), "A Perspective of Modern Methods in Computer-Aided Drug Design" by LMBalbes et al., Reviews in Computational Chemistry, Vol. 5, KB Lipkowitz and D.B. Boyd, eds., VCH, New York, pp. 337-380 (1994), and "Software For Structure-Based Drug Design" by W.C. Guida, J. Med. Chem., 1999, 11, pp. 1111-1112 (1999)). See also "Design", Curr. Opin. Struct. Biology, 4, pp. 777-781 (1994)).
[0204] After a chemical entity is designed or selected by the above methods, the efficiency with which the chemical entity may bind to the BTK binding pocket may be tested and optimized by computational evaluation. For example, an effective BTK binding pocket inhibitor should preferably be shown to have a relatively small energy difference between its bound and free states (i.e., a small deformation energy of binding). Thus, the most efficient BTK binding pocket inhibitors should be designed to have a deformation energy of binding of preferably about 10 kcal / mol or less, more preferably 7 kcal / mol or less. BTK binding pocket inhibitors may interact with the binding pocket in two or more conformations with similar overall binding energies. In such cases, the deformation energy of binding is considered to be the difference between the energy of the free chemical entity and the average energy of the conformations observed when the inhibitor is bound to the protein.
[0205] Chemical entities designed or selected to bind to the BTK binding pocket preferably may be further computationally optimized to not exhibit repulsive electrostatic interactions with the target enzyme and surrounding water molecules in their bound state, including repulsive charge-dipole, dipole-dipole and charge-dipole interactions.
[0206] Specific computer software is available in the art for evaluating the deformation energy and electrostatic interactions of compounds. Examples of programs designed for such purposes include Gaussian94, revision C (MJFrisch, Gaussian, Pittsburgh, PA (Copyright 1995)), AMBER, version 4.1 (PAKollman, University of California, San Francisco (Copyright 1995)), QUANTA / CHARMM (Molecular Simulations, San Diego, CA (Copyright 1998, 2000), Insight II / Discover (Molecular Simulations, San Diego, CA (Copyright 1998)), DelPhi (Molecular Simulations, San Diego, CA (Copyright 1998) and AMSOL (Quantum Chemistry Program Exchange, Indiana University). These programs can be run, for example, on Silicon Graphics workstations, such as Indigo2 with "IMPACT" graphics. Other hardware systems and software packages will be known to those skilled in the art.
[0207] Another method enabled by the present invention is to perform computational screening of small molecule databases for chemical entities or compounds that can bind in whole or in part to the BTK binding pocket, where the fit of such entities to the binding pocket can be determined either by shape complementarity or by estimated interaction energy (E. C. Meng et al., J. Comp. Chem., 13, pp. 505-524 (1992)).
[0208] According to another embodiment, the present invention provides a compound that associates with the BTK binding pocket generated or identified by the above methods.
[0209] Another particularly useful drug design technique enabled by the present invention is iterative drug design, a method for optimizing the association between a protein and a compound by determining and evaluating the three-dimensional structures of a successive set of protein / compound complexes.
[0210] In iterative drug design, crystals of a series of proteins or protein complexes are obtained and then the three-dimensional structure of each crystal is solved.
[0211] Such methods provide insight into the association between the proteins and compounds of each complex. This is accomplished by selecting a compound with inhibitory activity, obtaining crystals of this new protein / compound complex, solving the three-dimensional structure of the complex, and comparing the association between the new protein / compound complex and previously solved protein / compound complexes. By observing how changes in the compound affect the protein / compound associations, these associations can be optimized.
[0212] In some cases, iterative drug design is performed by forming successive protein-compound complexes and then crystallizing each new complex. High-throughput crystallization testing may be used to find new crystallization conditions or optimize the crystallization conditions of the original protein or complex for the new complex. Alternatively, pre-formed protein crystals may be soaked in the presence of an inhibitor, thereby forming a protein / compound complex, avoiding the need to crystallize each individual protein / compound complex.
[0213] The invention provides a data storage medium comprising the structural coordinates of a molecule or molecular complex of the BTK binding pocket. In one embodiment, the data storage medium comprises the structural coordinates of the binding pocket. The invention also provides a computer comprising the data storage medium. Such a storage medium, when read and utilized by a computer programmed with appropriate software, is capable of displaying a three-dimensional graphical representation of such a binding pocket on a computer screen or similar viewing device.
[0214] The present invention also provides methods for designing, evaluating and identifying compounds that bind to molecules or molecular complexes, or their binding pockets, such compounds being potential inhibitors of BTK or its homologs.
[0215] The present invention also provides methods for determining at least a portion of the three-dimensional structure of a molecule or molecular complex having at least some structurally similar characteristics to BTK, which is accomplished by using at least a portion of the structural coordinates obtained from a BTK protein or protein complex.
[0216] Some embodiments of the present invention are directed to a crystalline composition comprising SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0217] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0218] Some embodiments are directed to a method of identifying a candidate inhibitor of BTK, the method comprising: generating a three-dimensional structure of a binding site of BTK on a computer, the three-dimensional structure coordinates having the coordinates and space group parameters of a unit cell of a crystalline composition comprising SEQ ID NO:3 and Compound I; using the three-dimensional structure to design or select a candidate inhibitor; and contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK. In some embodiments, the candidate inhibitor forms a direct covalent bond with Cys481. In some embodiments, the candidate inhibitor forms a hydrogen bond with Lys430. In some embodiments, the candidate inhibitor forms a hydrogen bond with Met477. In some embodiments, the candidate inhibitor forms a hydrogen bond with Asp539.
[0219] Some embodiments provide a method of identifying and / or designing candidate inhibitors using a human BTK crystal comprising a human BTK protein, the method comprising: The present invention is directed to a method comprising: a) preparing a crystalline composition comprising SEQ ID NO:3 and compound I; b) soaking another candidate inhibitor in the crystalline composition and displacing the original ligand to form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) using the structural coordinates obtained in step c) to design and / or identify candidate inhibitors; and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0220] Some embodiments include a method of designing a compound or complex that interacts with a binding pocket or binding domain selected from the group consisting of (i) BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, and (ii) a BTK amino acid residue according to Table 2, comprising: (a) A compound of formula (I)
[0221] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of the backbone atoms is about 2.5 Å or less; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0222] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0223] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of the amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root-mean-square deviation from the backbone atoms of less than ±2.0 Å; (d) determining the binding site of the human BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify candidate inhibitors that interact with the binding site.
[0224] Some embodiments include (f) contacting the identified candidate inhibitor with BTK protein to determine the effect of the inhibitor on BTK activity.
[0225] In some embodiments, the binding site of the BTK protein determined in step (d) comprises structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, with a root mean square deviation of less than or equal to ±2.0 Å.
[0226] Some embodiments include a method of using a crystal comprising the BTK binding pocket or the BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I)
[0227] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) selecting potential inhibitors by performing rational drug design using the determined three-dimensional structure of the crystal, wherein the selecting step is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with the kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase.
[0228] Some embodiments include a method of designing a compound or complex that interacts with the BTK binding pocket or the BTK binding domain, comprising the steps of: (a) A compound of formula (I)
[0229] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0230] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0231] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structure coordinates obtained in step (b); and (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK.
[0232] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I)
[0233] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of a molecular complex comprising the binding sites for amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK.
[0234] Some embodiments of the present invention are directed to a crystalline composition consisting essentially of SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0235] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0236] Some embodiments are directed to a method of identifying a candidate inhibitor of BTK, the method comprising: generating a three-dimensional structure of a binding site of BTK on a computer, the three-dimensional structure coordinates having the coordinates and space group parameters of a unit cell of a crystalline composition comprising SEQ ID NO:3 and Compound I; using the three-dimensional structure to design or select a candidate inhibitor; and contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK. In some embodiments, the candidate inhibitor forms a direct covalent bond with Cys481. In some embodiments, the candidate inhibitor forms a hydrogen bond with Lys430. In some embodiments, the candidate inhibitor forms a hydrogen bond with Met477. In some embodiments, the candidate inhibitor forms a hydrogen bond with Asp539.
[0237] Some embodiments provide a method of identifying and / or designing candidate inhibitors using a human BTK crystal comprising a human BTK protein, the method comprising: The present invention is directed to a method comprising: a) preparing a crystalline composition consisting essentially of SEQ ID NO:3 and compound I; b) soaking another candidate inhibitor into the crystalline composition to displace the compound of formula (I) (the original ligand) and form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) designing or selecting a candidate inhibitor using the structural coordinates obtained in step c); and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0238] Some embodiments include a method of designing a compound or complex that interacts with a binding pocket or binding domain selected from the group consisting essentially of (i) BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, and (ii) a BTK amino acid residue according to Table 2, comprising the steps of: (a) A compound of formula (I)
[0239] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of the backbone atoms is about 2.5 Å or less; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first substance, the second substance and the at least one additional substance with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain and the first substance, the second substance and the at least one additional substance; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional substance that interacts with the binding pocket or binding domain.
[0240] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0241] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of the amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root-mean-square deviation from the backbone atoms of less than ±2.0 Å; (d) determining the binding site of the BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify candidate inhibitors that interact with the binding site.
[0242] Some embodiments include (f) contacting the identified candidate inhibitor with BTK protein to determine the effect of the inhibitor on BTK activity.
[0243] In some embodiments, the binding site of the BTK protein determined in step (d) consists essentially of the structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, with a root mean square deviation of less than or equal to ±2.0 Å.
[0244] Some embodiments include a method of using a crystal consisting essentially of the BTK binding pocket or the BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I)
[0245] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) selecting potential inhibitors by performing rational drug design using the determined three-dimensional structure of the crystal, wherein the selecting step is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with the kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase.
[0246] Some embodiments include a method of designing a compound or complex that interacts with the BTK binding pocket or the BTK binding domain, comprising the steps of: (a) A compound of formula (I)
[0247] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0248] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0249] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structure coordinates obtained in step (b); and (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK.
[0250] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I)
[0251] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists essentially of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of the molecular complex consisting essentially of binding sites for amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK.
[0252] Some embodiments of the present invention are directed to a crystalline composition consisting essentially of SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°. In some embodiments, the ligand is a compound of formula (I):
[0253] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0254] Some embodiments are directed to a method of identifying candidate inhibitors of BTK, the method comprising: generating a three-dimensional structure of a binding site of BTK on a computer, the three-dimensional structure coordinates having the coordinates and space group parameters of a unit cell of a crystalline composition consisting of SEQ ID NO:3 and Compound I; using the three-dimensional structure to design or select candidate inhibitors; and contacting the candidate inhibitors with human BTK and measuring the ability of the candidate inhibitors to bind to BTK. In some embodiments, the candidate inhibitors form a direct covalent bond with Cys481. In some embodiments, the candidate inhibitors form a hydrogen bond with Lys430. In some embodiments, the candidate inhibitors form a hydrogen bond with Met477. In some embodiments, the candidate inhibitors form a hydrogen bond with Asp539.
[0255] Some embodiments provide a method for identifying and / or designing candidate inhibitors using a human BTK crystal comprising a human BTK protein, the method comprising: The present invention is directed to a method comprising: a) preparing a crystalline composition consisting of SEQ ID NO:3 and compound I; b) soaking another candidate inhibitor in the crystalline composition to displace the compound of formula (I) (the original ligand) and form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); d) designing or selecting a candidate inhibitor using the structural coordinates obtained in step c); and e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK.
[0256] Some embodiments include a method of designing a compound or complex that interacts with a binding pocket or binding domain selected from the group consisting of: (i) BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, and (ii) a BTK amino acid residue according to Table 2, comprising the steps of: (a) A compound of formula (I)
[0257] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of the backbone atoms is about 2.5 Å or less; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0258] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0259] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of the amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root-mean-square deviation from the backbone atoms of less than ±2.0 Å; (d) determining the binding site of the human BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify candidate inhibitors that interact with the binding site.
[0260] Some embodiments include (f) contacting the identified candidate inhibitor with BTK protein to determine the effect of the inhibitor on BTK activity.
[0261] In some embodiments, the binding site of the BTK protein determined in step (d) consists essentially of the structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, with a root mean square deviation of less than or equal to ±2.0 Å.
[0262] Some embodiments include a method of using a crystal comprising the BTK binding pocket or the BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I)
[0263] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) selecting potential inhibitors by performing rational drug design using the determined three-dimensional structure of the crystal, wherein the selecting step is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with the kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase.
[0264] Some embodiments include a method of designing a compound or complex that interacts with the BTK binding pocket or the BTK binding domain, comprising the steps of: (a) A compound of formula (I)
[0265] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0266] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0267] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structure coordinates obtained in step (b); and (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK.
[0268] Some embodiments provide a method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I)
[0269] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK consists of SEQ ID NO:3, the crystal being characterized by space group p22121 and having unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of the molecular complex consisting essentially of binding sites for amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK.
[0270] Methods for determining the ability of a candidate inhibitor to bind to BTK Aspects of the present disclosure also include using a BTK binding assay to determine the ability of a candidate inhibitor to bind to BTK. In some embodiments, a BTK binding assay is used to determine the level of BTK occupancy by a candidate inhibitor, including but not limited to the compounds of the present disclosure. Also described herein are methods and kits for use in combination with the methods described herein to identify candidate inhibitors. In some embodiments, the methods provided include a protein occupancy assay for one or more candidate inhibitors of BTK. Thus, a protein occupancy assay for a BTK inhibitor is described herein. In certain embodiments, a protein occupancy assay is described herein that is an ELISA probe assay. In some embodiments, the ELISA probe assay is a plate-based electrochemilummescent assay that measures the relative amount of BTK that is not bound by the candidate inhibitor. For example, in some embodiments, the candidate inhibitor binds to the active site of BTK and forms a disulfide bond with a cysteine residue. In some embodiments, the assay includes binding an activity probe to free BTK that is not bound by the candidate inhibitor. In some embodiments, the activity probe comprises a BTK inhibitor attached to a detectable label (e.g., biotin) via a linker (e.g., a long-chain linker). Labeling of the sample with the probe allows for detection of BTK that is not occupied by a drug. In some embodiments, the BTK-conjugated probe is captured by a streptavidin-coated plate. In some embodiments, excess unconjugated probe competes with the probe-labeled BTK for binding to streptavidin. Also described herein are methods for determining the effectiveness of an inhibitor of BTK. Some embodiments are methods for determining the effectiveness of a protein modulator (e.g., an inhibitor drug) against a target (e.g., a target protein kinase). In some embodiments, a method is provided for determining the effectiveness of a candidate inhibitor against a target kinase (e.g., BTK).In some aspects, the method includes: (a) contacting a sample containing BTK with a probe to form a probe-bound target kinase; (b) detecting the amount of the probe-bound target kinase in the sample; and (c) determining the effectiveness of a candidate inhibitor based on the amount of the probe-bound target kinase. In some aspects, the method further includes contacting the sample with a candidate inhibitor (e.g., combining the sample with the probe) prior to step (a). In some aspects, detecting the amount of the probe-bound target kinase includes adding a candidate inhibitor, reagent, or buffer to detect the probe-bound kinase. In some aspects, the candidate inhibitor, reagent, or buffer includes horseradish peroxidase (HRP), detection antibody buffer, read buffer, wash buffer. In some aspects, detecting the presence or absence of the probe-bound target kinase includes quantifying the amount of the probe-bound target kinase. In some aspects, the quantifying step includes fluorescence, immunofluorescence, chemiluminescence, or electrochemiluminescence. In some aspects, determining the effectiveness of the BTK inhibitor includes determining the occupancy of the target kinase by the BTK inhibitor. In some embodiments, the amount of probe-bound target kinase is inversely correlated with the efficacy of the BTK inhibitor. For example, when a sample treated with a candidate inhibitor (e.g., a sample such as a blood sample or tumor tissue that has been contacted with a candidate inhibitor before contacting with the probe) is contacted with the probe, as the amount of probe-bound target kinase (e.g., unoccupied target kinase) detected increases, the efficacy of the candidate inhibitor decreases. In another example, when a sample treated with a drug is contacted with the probe, as the amount of probe-bound target kinase (e.g., unoccupied target kinase) detected decreases, the efficacy of the drug increases. In some embodiments, the amount of probe-bound target kinase is directly correlated with the efficacy of the candidate inhibitor. For example, when an untreated sample (e.g., a sample that has not been contacted with a drug before contacting with the probe) is contacted with the probe, as the amount of probe-bound target kinase detected increases, the efficacy of the candidate inhibitor also increases.In another example, when an untreated sample (e.g., a sample that has not been contacted with a candidate inhibitor prior to contacting with a probe) is contacted with a probe, the effectiveness of the candidate inhibitor decreases as the amount of probe-bound target kinase detected decreases. In some embodiments, the candidate inhibitor is determined to be effective when it binds to at least about 50% of the target kinases. Alternatively, the drug is determined to be effective when it binds to at least about 60% of the target kinases. In some embodiments, the candidate inhibitor is determined to be effective when it binds to at least about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97% or about 99% of the target kinases. In some embodiments, the assay is performed on a sample obtained from a subject (e.g., a mammal) to which a candidate inhibitor has been administered. In some embodiments, the sample is taken about 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks or more after administration of the candidate inhibitor. In some embodiments, the probe comprises an agent and a label. In some examples, the agent is fused to the label. In other examples, the agent is attached to the label. In another example, the agent is attached to the label by a linker. In some embodiments, the agent and the candidate inhibitor are essentially the same thing. In some embodiments, the probe comprises a label. In some embodiments, the probe comprises a label and a linker. In some embodiments, the agent and candidate inhibitor are at least about 20% identical, at least about 30% identical, at least about 40% identical, at least about 50% identical, at least about 60% identical, at least about 70% identical, at least about 80% identical, at least about 90% identical, or at least about 95% identical, hi other embodiments, the agent and candidate inhibitor are different.In some embodiments, the drug and candidate inhibitor are at least about 5% different, at least about 10% different, at least about 20% different, at least about 30% different, at least about 40% different, at least about 50% different, at least about 60% different, at least about 70% different, at least about 80% different, at least about 90% different, or at least about 95% different.
[0271] Disclosed herein is a protein occupancy assay kit comprising a linker, a label, a drug, or any combination thereof. In one aspect, a protein occupancy assay kit comprising a linker and a label, where the linker is capable of binding the label to the drug, and the drug is a protein modulator. In another aspect, a protein occupancy assay kit comprising a drug, a linker, and a label, where the linker is capable of binding the drug and the label, thereby binding the drug to the label. In some aspects, a protein occupancy assay kit comprising a probe, where the probe comprises a drug bound to the label. In some aspects, a protein occupancy assay kit comprising a probe, where the probe comprises a drug bound to the linker. In some aspects, a protein occupancy assay kit comprising a drug and a solid support, where the drug is bound to the solid support. In another aspect, a protein occupancy assay kit comprising a label and a solid support, where the label is bound to the solid support. In another aspect, a protein occupancy assay kit comprising a probe and a solid support, where the probe comprises a drug, a linker, a label, or any combination thereof. In some aspects, the protein occupancy assay kit comprises a target (e.g., a protein) and a solid support, the target being bound to the solid support. In some aspects, any of the kits disclosed herein further comprises a label. In some aspects, any of the kits disclosed herein further comprises a linker. In some aspects, any of the kits disclosed herein further comprises an agent. In some aspects, any of the kits disclosed herein further comprises a plurality of linkers, the linker being capable of binding to another linker, an agent, a label, or any combination thereof. In some aspects, any of the kits disclosed herein further comprises a probe. In some aspects, the probe comprises an agent, a linker, a label, or any combination thereof. In some aspects, any of the kits disclosed herein further comprises a target (e.g., a protein). Exemplary aspects of agents, linkers, labels, probes, solid supports, and targets are disclosed herein.Exemplary methods for attaching a probe or a target to a solid support are further disclosed herein.
[0272] In some aspects, the methods, kits, and compositions disclosed herein include a probe. In some aspects, the probe includes an agent and a label. In some aspects, the agent and the label are conjugated. In other aspects, the probe includes an agent and a linker. In some aspects, the agent and the linker are conjugated. In another aspect, the probe includes an agent, a linker, and a label. In some aspects, the agent, the linker, and / or the label are conjugated to each other. In some aspects, the probe includes a label. In another aspect, the probe includes a label and a linker. In some aspects, the label and the linker are conjugated. In some aspects, the conjugation is by chemical, enzymatic, or cross-linking methods. In some aspects, the probe is conjugated to a solid support. Exemplary aspects of agents, linkers, labels, and solid supports are disclosed herein.
[0273] Any of the assays and systems disclosed herein may be useful for researching and validating candidate inhibitors. Provided herein is a method for validating a candidate inhibitor, the method comprising: (a) contacting a sample containing a target with a probe to form a probe-bound target; (b) detecting the presence or absence of the probe-bound target; and (c) determining the occupancy of the target by the candidate inhibitor based on the presence or absence of the probe-bound target, thereby validating the candidate inhibitor.
[0274] Further provided herein is a method for determining occupancy of a target, the method comprising: (a) combining a sample containing a target with a probe; (b) detecting the presence or absence of probe-bound target; and (c) determining occupancy of the target by candidate inhibitors based on the presence or absence of probe-bound target.
[0275] In some embodiments, the method further comprises capturing the target prior to step (a) of contacting the sample with the probe. In some embodiments, the target is captured by an antibody. In some embodiments, the antibody is an anti-target antibody. In some embodiments, the antibody is bound to a solid support. In some embodiments, the solid support is a microplate. In some embodiments, the microplate is an MSD microplate.
[0276] In yet other embodiments, the method further comprises contacting the probe-bound target with a first detection agent. In some embodiments, the first detection agent comprises an antibody, a bead, a dye, or a fluorophore. In some embodiments, the first detection agent comprises an antibody. In some embodiments, the antibody is an anti-BTK antibody. In some embodiments, the method further comprises contacting the detection agent with a second detection agent. In some embodiments, the second detection agent comprises an antibody, a bead, a dye, or a fluorophore. In some embodiments, the first detection agent is labeled. In some embodiments, the second detection agent is labeled. In some embodiments, the label is an electrochemiluminescent tag. In some embodiments, the electrochemiluminescent tag comprises tris(bipyridine)ruthenium(II) dicfiloride. In some embodiments, the electrochemiluminescent tag is ruthenium(II) tris-bipyridine, N-hydroxysuccinimide. In some embodiments, the label is a SULFO TAG.
[0277] In some embodiments, detecting the presence or absence of probe-bound target comprises contacting the sample with a solid support. In some embodiments, the solid support comprises beads. In some embodiments, the beads are streptavidin beads. In some embodiments, the beads are magnetic beads. In some embodiments, the beads are labeled beads. In some embodiments, the beads are labeled streptavidin beads. In some embodiments, the beads are labeled with an electrochemiluminescent tag. In some embodiments, the electrochemiluminescent tag comprises tris(bipyridine)ruthenium(II) dicfiloride. In some embodiments, the electrochemiluminescent tag is ruthenium(II) tris-bipyridine, N-hydroxysuccinimide. In some embodiments, the beads are SULFO TAG beads. In some embodiments, the beads are SULFO TAG streptavidin beads.
[0278] In some embodiments, the bead interacts with the probe. In some embodiments, the probe comprises a label. In some embodiments, the label comprises biotin. In some embodiments, the bead interacts with the biotin. In some embodiments, the bead forms a conjugate with the probe-bound target. In some embodiments, the bead is conjugated to the probe.
[0279] In some embodiments, detecting the presence or absence of the probe-bound target comprises detecting the probe-bound target or a portion thereof. In some embodiments, detecting the presence or absence of the probe-bound target comprises detecting a bead or a portion thereof. In some embodiments, detecting the presence or absence of the probe-bound target comprises detecting a labeled bead. In some embodiments, detecting the presence or absence of the probe-bound target comprises detecting an electrochemiluminescent tag. In some embodiments, the electrochemiluminescent tag comprises tris(bipyridine)ruthenium(II)dichloride. In some embodiments, the electrochemiluminescent tag is ruthenium(II)tris-bipyridine, N-hydroxysuccinimide. In some embodiments, detecting the presence or absence of the probe-bound target comprises detecting a SULFO TAG. In some embodiments, the detecting step comprises luminescence. In some embodiments, the detecting step comprises electrochemiluminescence.
[0280] In some aspects, the method further comprises purifying the probe-bound target. In some aspects, the probe-bound target is an unoccupied target. In some aspects, the probe-bound target is a drug-occupied target. In another aspect, purifying the probe-bound target comprises magnetic separation of the probe-bound target from the non-probe-bound target.
[0281] In some embodiments, the sample is a pre-treated sample, and the pre-treated sample is contacted with the drug prior to contacting with the probe, hi some embodiments, the sample is an untreated sample, and the sample is not contacted with the candidate inhibitor prior to contacting with the label.
[0282] In some aspects, the probe comprises an agent. In some aspects, the probe comprises an agent and a linker. In some aspects, the probe comprises a label. In some aspects, the probe comprises a label and a linker. In some embodiments, the agent is a known BTK inhibitor. In some aspects, the agent is a compound of Formula (I). In some aspects, the BTK inhibitor is a reversible BTK inhibitor. In some aspects, the agent is a and the BTK inhibitor is an irreversible BTK inhibitor. In some aspects, the agent is a and the BTK inhibitor is a selective covalent BTK inhibitor. In some aspects, the agent is a and the BTK inhibitor forms a covalent bond with a cysteine residue of Bruton's tyrosine kinase (BTK). In some aspects, the cysteine residue is cysteine 481. In some aspects, the agent is a and the BTK inhibitor is a compound of Formula (I).
[0283] In some embodiments, validating the drug comprises determining the effectiveness of the candidate inhibitor against the target. In some embodiments, determining the occupancy of the target by the drug comprises quantifying the presence or absence of probe-bound target. In some embodiments, the candidate inhibitor is effective when the occupancy of the target is at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99%.
[0284] Further disclosed herein is a method for determining the effectiveness of a test agent, comprising: (a) combining a sample containing a target with a probe; (b) detecting the presence or absence of the probe-bound target; and (c) determining the effectiveness of the test agent based on the presence or absence of the probe-bound target. Further disclosed herein is a method for identifying a drug responder, comprising: (a) combining a sample containing a target with a probe; (b) detecting the presence or absence of the probe-bound target; and (c) identifying a drug responder based on the presence or absence of the probe-bound target. Further disclosed herein is a method for identifying a BTK inhibitor, comprising: (a) combining a sample containing a target with a probe; (b) detecting the presence or absence of the probe-bound target; and (c) identifying a kinase modulator based on the presence or absence of the probe-bound target. Further disclosed herein is a method for determining drug resistance, comprising: (a) combining a sample containing a target with a probe; (b) detecting the presence or absence of the probe-bound target; and (c) determining drug resistance based on the presence or absence of the probe-bound target.
[0285] In some embodiments, the methods, assays, and systems disclosed herein include contacting a sample containing a target with a probe. Samples suitable for use in any of the methods, assays, and systems disclosed herein include, but are not limited to, whole blood samples, peripheral blood samples, lymph samples, tissue samples, tumor biopsy samples, bone marrow samples, or other bodily fluid samples. In some embodiments, the sample is a sample containing one or more cell types or lysates thereof from a whole blood sample, peripheral blood sample, lymph sample, tissue sample, tumor biopsy sample, bone marrow sample, or other bodily fluid sample. Examples of bodily fluids include, but are not limited to, smears, sputum, biopsies, secretions, cerebrospinal fluid, bile, blood, lymph, saliva, and urine. In some embodiments, the cells of the sample are isolated from other components of the sample before use in the provided methods. In some embodiments, a particular cell type of the sample is isolated from other cell types of the sample before use in the provided methods. For example, in some embodiments, peripheral blood mononuclear cells (PBMCs, e.g., lymphocytes, monocytes, and macrophages) of a blood sample are isolated from other cell types of the blood sample prior to use in the methods provided. For example, in some embodiments, lymphocytes (e.g., B cells, T cells, or NK cells) of the sample are isolated from other cell types of the sample prior to use in the methods provided. For example, in some embodiments, B cells of the sample are isolated from other cell types of the sample prior to use in the methods provided. In some embodiments, cells of the sample are lysed prior to use in the methods provided. For example, in some embodiments, cancer cells are isolated from normal cells of the sample prior to use in the methods provided.
[0286] Any of the samples disclosed herein contain a complex population of cells, which can be assayed as a population or separated into subpopulations. Such cellular and acellular samples can be separated by centrifugation, elutriation, density gradient separation, apheresis, affinity selection, panning, FACS, filtration, centrifugation through Hypaque, etc. Relatively homogeneous cell populations can be obtained by using antibodies specific to markers identified with particular cell types. Alternatively, heterogeneous cell populations can be used.
[0287] Once a sample is obtained, it can be used directly, frozen, or maintained in a suitable culture medium for a short period of time. Methods for isolating one or more cells for use according to the methods of the invention are performed according to standard techniques and protocols well established in the art. In some embodiments, a sample is obtained from a subject. Such a subject can be a human or a livestock animal, such as a cow, chicken, pig, horse, rabbit, dog, cat, or goat. In some embodiments, cells used in the invention are taken from a patient. Samples from animals, such as humans, can include, for example, whole blood, sweat, tears, saliva, ear flow, sputum, lymph, bone marrow suspension, lymph, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, respiratory, intestinal, or genitourinary tract secretions, tissue or organ (e.g., lung) washings, or tissues that have been removed from organs such as the breast, lung, intestine, skin, cervix, prostate, pancreas, heart, liver, and stomach.
[0288] To obtain a blood sample, any technique known in the art can be used, such as a syringe or other vacuum suction device. The sample can be optionally pretreated or processed before enrichment. Examples of pretreatment steps include the addition of reagents such as stabilizers, preservatives, fixatives, lysis reagents, diluents, drugs, anti-apoptotic reagents, anticoagulant reagents, antithrombotic reagents, magnetic property adjustment reagents, buffer reagents, osmotic pressure adjustment reagents, pH adjustment reagents, and / or cross-linking reagents. For example, when a blood sample is obtained, preservatives such as anticoagulants and / or stabilizers can be added to the sample before enrichment.
[0289] A sample, such as a blood sample, can be analyzed under any of the methods, assays, and systems disclosed herein within 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hours, 6 hours, 3 hours, 2 hours, or 1 hour from the time the sample was obtained.
[0290] In some embodiments, the sample can be combined with an enzyme or compound that selectively lyses one or more cells or components in the sample. For example, in a blood sample, platelets and / or enucleated red blood cells are selectively lysed to produce a sample enriched for nucleated cells. Cells of interest can then be separated from the sample using methods known in the art.
[0291] When a sample (e.g., a blood sample) is obtained from a subject, the amount can vary depending on the size of the subject and the condition being screened for. In some embodiments, up to 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mL of sample is obtained. In some embodiments, 1-50, 2-40, 3-30, or 4-20 mL of sample is obtained. In some embodiments, more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mL of sample is obtained.
[0292] Aspects of the present disclosure include methods of monitoring the effectiveness of a candidate inhibitor. In some embodiments, a BTK occupancy rate of greater than about 75% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, a BTK occupancy rate of greater than about 80% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, a BTK occupancy rate of greater than about 90% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, a BTK occupancy rate of greater than about 95% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, a BTK occupancy rate of greater than about 99% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, a BTK occupancy rate of greater than about 100% indicates that the candidate inhibitor is therapeutically effective.
[0293] Aspects of the present disclosure include using the BTK lanthascreen™ binding assay to determine BTK occupancy by BTK inhibitors. In some embodiments, the BTK lanthascreen™ binding assay monitors compound binding to the unphosphorylated BTK kinase domain (UP-BTK) by competing with a fluorescently labeled tracer. In some embodiments, UP-BTK, consisting of the kinase domain of the unphosphorylated BTK protein (389-659aa), is produced in a baculovirus / insect cell expression system. In some embodiments, 2 ng of GST-tagged human BTK (389-659aa) is incubated with a BTK inhibitor compound, 50 nM tracer 236, and 2 nM anti-GST antibody in a 384-well plate for 60 minutes using an optimized Lanthascreen™ assay. In some embodiments, after 60 minutes, plates are read at 340 nM and 615 / 665 nM in a multifunction plate reader such as the Infinite F500 (Tecan). In some embodiments, data is analyzed using Xlfit™ version 5.3 from ID Business Solutions (Guildford), a Microsoft Excel add-in.
[0294] In some embodiments, binding of a candidate inhibitor to BTK in the assays described herein may be indicative of its functionality in using the candidate inhibitor in a patient in need of treatment for a disease or condition. In some embodiments, a BTK occupancy rate of greater than about 75% indicates that the candidate inhibitor is therapeutically effective. In some embodiments, binding of a candidate inhibitor to BTK in the assays described herein may be predictive of the ability of a compound to inhibit BTK and thereby treat a disease or condition. In some embodiments, a BTK occupancy rate of greater than about 75% indicates that the candidate inhibitor will effectively inhibit BTK. In yet other embodiments, binding of a candidate inhibitor to BTK in the assays described herein may be predictive of the in vivo activity of a particular candidate inhibitor based on showing similar BTK occupancy in the assays. In some embodiments, a BTK occupancy rate of greater than about 75% indicates that the candidate inhibitor will be therapeutically effective in vivo. EXAMPLES
[0295] The following examples are offered for illustrative purposes only and are not intended to limit the invention in any manner.
[0296] Example 1. Cloning and construction of recombinant baculovirus All cloning steps were performed using standard molecular biology protocols using molecular biology kits from Qiagen, restriction enzymes were from New England Biolabs, and PfuUltra™ DNA polymerase was from Stratagene. pFastBac1, the Bac-to-Bac system, and all insect cell media / components were from Invitrogen.
[0297] The gene for the kinase domain of human BTK was amplified from first strand cDNA (MegaMan™ Human Transcriptome Library, Stratagene). The coding region for amino acids 389-659 of human BTK was fused to a DNA sequence encoding GST followed by a TEV protease cleavage site and cloned into the vector pFastBac1 using BamHI and XhoI restriction sites. After DNA sequencing was performed to confirm the integrity of the entire insert, the plasmid was used to generate recombinant bacmid-DNA using the Bac-to-Bac® system. The DNA and protein sequences are presented as SEQ ID NO:1 (BTK DNA), SEQ ID NO:2 (GST portion of BTK protein) and SEQ ID NO:3 (BTK kinase domain protein).
[0298] Bacmid-DNA was transfected into Sf9 cells to generate recombinant baculovirus (P1-virus) according to standard protocols. P2 virus stock was amplified by infecting 15 mL of Sf9 cells (0.5×106 cells / mL in a 75 cm2 dish) in Grace's medium supplemented with 10% FCS and 0.1% Pluronic® with 500 μL of P1 virus and incubating at 26° C. for 1 week.
[0299] For generation of high-titer virus stocks (HTVS), 500 mL of Sf9 cells (2 x 106 cells / mL in glass spinner flasks) in Grace's medium supplemented with 10% FCS and 0.1% Pluronic® were infected with 4 mL of virus P2 stock and incubated at 26°C for 6 days.
[0300] Example 2. Expression of Recombinant Human BTK Kinase Domain For expression of recombinant human BTK kinase domain by a titerless infection protocol, 5 L of Sf9 in Grace's medium supplemented with 10% FCS and 0.1% Pluronic® (2×106 cells / mL in a 10 L CultiBag, Sartorius Stedim) were infected into 140 mL of HTVS (prepared as described above) and grown for 64 h at 26° C. with aeration on a BioWave® 50SPS (Wave Biotech) (0.1 L / min, 21 rocking motions per minute at a 10° angle). After expression, cells were harvested by centrifugation and stored frozen (−80° C.) until purification.
[0301] Example 3. Expression of Recombinant Human BTK Kinase Domain Buffers were prepared and pH values were adjusted at room temperature. To prepare PBS buffers, 10x stock solutions were diluted. All chromatography buffers were prepared and pH values were adjusted at room temperature. Chromatography buffers were filtered (0.22 μm), degassed and cooled to 4° C. before use. Reducing agents were added immediately before use. 10x PBS 1.4M NaCl 100mM Na2HPO4 18mM NaH2PO4 27 mM KCl Buffer A 1x PBS 5mM β-ME Final pH (HCl) = 7.3 (room temperature) Buffer B 20 mM Tris, pH=8.0 150mM NaCl 10mM reduced glutathione (GSH) 2mM DTT Final pH (HCl) = 8.0 (room temperature) Buffer C 20 mM Tris / HCl, pH=8.0 150mM NaCl 2mM DTT
[0302] All purification steps were performed at 4°C on a chromatography station and columns (AKTA™ system) from GE Health Care unless otherwise stated. Between purification steps, the protein was kept on ice or in a cold room / refrigerator at 4°C. Recombinant TEV protease was prepared in-house as a His-tagged protein (expressed in E. coli as a soluble protein). All buffers were prepared, pH adjusted at room temperature, and then cooled to 4°C. Chromatography buffers were filtered (0.22 μm) and degassed before use. Reducing agent was added immediately before use. Before pooling the proteins, samples were analyzed on precast SDS-gels (10%) from Invitrogen. The isolated human BTK kinase domain has a tendency to precipitate during purification, resulting in a relatively low yield of purified protein.
[0303] Frozen cell pellets from 5L expression cultures were thawed in 200mL of Buffer A (1x PBS, 5mM β-ME) supplemented with 4 "Complete™, EDTAfree Protease Inhibitor Cocktail Tablets" (Roche Applied Science) and disrupted using an Ultrathurax (Heidolph). Insoluble material was pelleted by centrifugation at 51000g for 30 min. The first capture step was performed in batch mode by mixing the cleared lysate with 10mL of GSH-Sepharose beads (GE Health Care) equilibrated in Buffer A and incubating at 4°C for 2 hours. The mixture was centrifuged at 700g for 10 min to pellet the GSH-beads and the supernatant was discarded. The beads were washed twice with 40mL of Buffer A and centrifuged as above. The washed beads were mixed with 5mL of Buffer A and loaded into an empty chromatography column (XK16 / 20, GE Health Care). The column was packed by gravity flow, connected to the AKTA™ Prime system, and washed at a flow rate of 2 mL / min with Buffer A. After a stable baseline of UV absorbance at 280 nm was reached, the buffer was exchanged into Buffer B (20 mM Tris, pH=8.0, 150 mM NaCl, 10 mM reduced glutathione (GSH), 2 mM DTT) and the proteins bound to the column were eluted at a flow rate of 2 mL / min.
[0304] After SDS-gel analysis, fractions containing the GST-tagged human BTK kinase domain were pooled and the protein concentration was determined to be 2.1 mg / mL by standard Bradford assay.
[0305] The pooled proteins were digested overnight with 1.5 mg of recombinant His-tagged TEV protease and thereby dialyzed against 2 L of buffer A. Proteins precipitated during dialysis were pelleted by centrifugation at 4000 g for 10 min and the supernatant of the centrifugation step was applied to the column used in the first affinity step and equilibrated with buffer A at a flow rate of 2 mL / min. The column flow-through was collected and washed with buffer A, after which the bound proteins were eluted with 100% buffer B. This step was immediately repeated with the flow-through collected from the first run.
[0306] The pooled flow-through from the second run was concentrated to a volume of approximately 18 mL using a Millipore Amicon® ultrafiltration device with a cut-off of 10 kDa as per the manufacturer's instructions. The concentrated sample was buffer exchanged by performing size-exclusion chromatography on a Superdex™ 75 26 / 60 column equilibrated with buffer B (20 mM Tris / HCl, pH=8.0, 150 mM NaCl, 2 mM DTT) at a flow rate of 2 mL / min in two separate runs. To remove traces of His-tagged TEV protease, a 1 mL HisTrap™ column was directly connected to the outlet of the Superdex™ column. This procedure efficiently removed contaminating proteins, but peak broadening by the HisTrap™ column had to be accepted.
[0307] Human BTK kinase domain eluted in a peak centered at a retention volume of approximately 190 mL. Pure protein was pooled after SDS-gel analysis and concentrated as above to a final concentration of approximately 8-13 mg / mL as determined by a standard Bradford assay. The procedure described here yields approximately 2.5 mg of protein suitable for crystallization from a 5 L expression culture.
[0308] Example 4. Crystallization of recombinant human BTK kinase domain Human BTK kinase domain residues 389-659 in 20 mM Tris (pH 8.0), 150 mM NaCl, and 2 mM dithiothreitol were mixed with a 2-fold excess of compound I, incubated overnight at 4 °C, and concentrated to 8 mg / ml. Crystallization of BTK Compound I complexes were grown by hanging drop vapor diffusion method at 4 °C using NeXtal EasyXtal 15-well plates. Crystals were obtained overnight using a 1:1 mixture of protein complex and well solution droplets (25-33% PEG MME 5K, 100 mM MES (pH 6.35-6.75), 200 mM ammonium sulfate), and microseeds were added to the droplets at a ratio of 0.2. Microseed stocks were made using BTK complexed with 5 mM adenosine crystals grown in similar conditions, and these crystals were collected in stabilizing solution and vortexed to make seed stocks.
[0309] Example 5. Structure determination and refinement Recovered crystals were briefly transferred to a cryoprotectant solution consisting of 80% well solution and 20% ethylene glycol and flash frozen in liquid nitrogen. The data set was collected using the IMCA17-ID beamline at the Advanced Photon Source (Argonne National Laboratory). Data were processed with HKL2000 (Otwinowski and Minor, 1997). COOT was used for model building. The phase information required to determine and analyze the structure was obtained by molecular replacement with previously solved structures. Ligand restraints were generated with PHENIX.elbow and the structure was refined with PHENIX.refine (Liebschner et al., 2019). The structure was solved using Coot (Emsley et al., 2010), MOE (Chemical Computing Group), and Pymol (Schrodinger). Crystals diffracted to 1.9 Å. Data collection and refinement statistics are shown in Table 1. Coordinates of the BTK-inhibitor complex are shown in Table 2. Clear electron density was observed for the compound, including a direct bond to Cys481 (Figure 2).
[0310] The structure of human BTK complexed with compound I adopts a bilobed structure characteristic of other members of the eukaryotic protein kinase family. The ligand is located in a cleft formed between the N- and C-terminal lobes and binds to the ATP-binding site and adjacent regions of the active site (Figure 3). There is one monomer in the asymmetric unit, and the model includes residues Gly389 to Glu568.
[0311] Electron density maps clearly show the ligand-binding site and the amino acid residues that form the ligand, and interpretation of the X-ray diffraction data reveals a distinct binding mode and the orientation and conformation of the ligand bound to the binding site.
[0312] result Covalent bonds were observed between the acrylamide moiety of compound I and the sulfur atom of Cys481 of BTK. Hydrogen bonds were observed between compound I and residues Asp539, Lys430, and Met477. Solvent molecules were also observed in hydrogen bonds with compound I (Figure 4).
[0313] Residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 are found in the vicinity of compound I with a maximum distance of 4.0 Å (Figure 5).
[0314] References PHENIX:Determination of macromolecular structure using X-rays,neutrons and electrons:recent developments in Phenix, D. Liebschner, PVAfonine, MMLBaker, G. Bunkoczi, VBChen, TICroll, B. Hintze, L.-W. Hung, S. Jain, AJ McCoy, NWMoriarty, RDOeffner, BKPoon, MGPr isant, RJRead, JSRichardson, DCRichardson, MDSammito, OVSobolev, DHStockwell, TCTerwilliger, AGUrzhumtsev, LLVideau, C.Williams, and PDAdams, Acta Cryst.(2019).D75,861–877
[0315] COOT:Features and Development of Coot by Paul Emsley, Bernhard Lohkamp, William G. Scott, and Kevin Cowtan, Acta Crystallographica Section D-Biological Crystallography, 2010, Vol 66, 486-501.
[0316] HKL-2000:Z.Otwinowski and W.Minor,Processing of X-ray Diffraction Data Collected in Oscillation Mode,Methods in Enzymology,Volume 276:Macromolecular Crystallography,part A,p.307-326,1997,CWCarter,Jr.and RMSweet,Academic Press.
[0317] IMCA-CAT Acknowledgement: Use of IMCA-CAT beamline 17-ID (or 17-BM) at the Advanced Photon Source was supported by the Industrial Macromolecular Crystallography Association, Inc. through a contract with the Hauptmann-Woodward Medical Institute.
[0318] This work utilized resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, which is supported by the Industrial Macromolecular Crystallography Association companies through a contract with the Hauptmann-Woodward Medical Institute.
[0319] Advanced Photon Source (APS) Acknowledgement: This work used resources at the Advanced Photon Source, a Department of Energy (DOE) Office of Science User Facility operated by Argonne National Laboratory for the U.S. Department of Energy (DOE) Office of Science under Contract No. DE-AC02-06CH11357.
[0320] [Table 2]
[0321] Table 2 lists the atomic structure coordinates of human BTK complexed with compound I, in a Protein Data Bank (PDB)-like format and headers, derived by X-ray diffraction from crystals of the complex obtained by ligand co-crystallization.
[0322] The following abbreviations are used in Table 2. Residue "LIG" represents compound I. Structural diagrams were generated using PyMOL (The PyMOL Molecular Graphics System, Version 2.4.0, Schrodinger).
[0323] [Table 3-1]
[0324] [Table 3-2]
[0325] [Table 3-3]
[0326] [Table 3-4]
[0327] [Table 3-5]
[0328] [Table 3-6]
[0329] [Table 3-7]
[0330] [Table 3-8]
[0331] [Table 3-9]
[0332]
Table 3-10
[0333]
Table 3-11
[0334]
Table 3-12
[0335]
Table 3-13
[0336]
Table 3-14
[0337]
Table 3-15
[0338]
Table 3-16
[0339]
Table 3-17
[0340]
Table 3-18
[0341]
Table 3-19
[0342]
Table 3-20
[0343]
Table 3-21
[0344]
Table 3-22
[0345]
Table 3-23
[0346]
Table 3-24
[0347]
Table 3-25
[0348]
Table 3-26
[0349]
Table 3-27
[0350]
Table 3-28
[0351]
Table 3-29
[0352]
Table 3-30
[0353]
Table 3-31
[0354]
Table 3-32
[0355]
Table 3-33
[0356]
Table 3-34
[0357]
Table 3-35
[0358]
Table 3-36
[0359]
Table 3-37
[0360]
Table 3-38
[0361]
Table 3-39
[0362]
Table 3-40
[0363]
Table 3-41
[0364]
Table 3-42
[0365]
Table 3-43
[0366]
Table 3-44
[0367]
Table 3-45
[0368]
Table 3-46
[0369]
Table 3-47
[0370]
Table 3-48
[0371]
Table 3-49
[0372]
Table 3-50
[0373]
Table 3-51
[0374]
Table 3-52
[0375]
Table 3-53
[0376]
Table 3-54
[0377]
Table 3-55
[0378]
Table 3-56
[0379]
Table 3-57
[0380]
Table 3-58
[0381]
Table 3-59
[0382]
Table 3-60
[0383]
Table 3-61
[0384]
Table 3-62
[0385]
Table 3-63
[0386]
Table 3-64
[0387]
Table 3-65
[0388]
Table 3-66
[0389]
Table 3-67
[0390]
Table 3-68
[0391]
Table 3-69
[0392]
Table 3-70
[0393]
Table 3-71
[0394]
Table 3-72
[0395]
Table 3-73
[0396]
Table 3-74
[0397]
Table 3-75
[0398]
Table 3-76
[0399]
Table 3-77
[0400]
Table 3-78
[0401]
Table 3-79
[0402]
Table 3-80
[0403]
Table 3-81
[0404]
Table 3-82
[0405]
Table 3-83
[0406]
Table 3-84
[0407]
Table 3-85
[0408]
Table 3-86
[0409]
Table 3-87
[0410]
Table 3-88
[0411]
Table 3-89
[0412]
Table 3-90
[0413]
Table 3-91
[0414]
Table 3-92
[0415]
Table 3-93
[0416]
Table 3-94
[0417]
Table 3-95
[0418]
Table 3-96
[0419]
Table 3-97
[0420]
Table 3-98
[0421]
Table 3-99
[0422]
Table 3-100
[0423]
Table 3-101
[0424]
Table 3-102
[0425]
Table 3-103
[0426]
Table 3-104
[0427]
Table 3-105
[0428]
Table 3-106
[0429]
Table 3-107
[0430]
Table 3-108
[0431]
Table 3-109
[0432]
Table 3-110
[0433] [Table 3-111]
[0434] [Table 3-112]
[0435] [Table 3-113]
[0436] [Table 3-114]
[0437] [Table 3-115]
[0438] [Table 3-116]
[0439] [Table 3-117]
[0440] [Table 3-118]
[0441] [Table 3-119]
[0442] While the foregoing specification, together with examples given for purposes of illustration, teaches the principles of the invention, it will be understood that the practice of the invention encompasses all ordinary modifications, adaptations and / or alterations that come within the scope of the following claims and equivalents thereto.
[0443] Embodiment The following list of embodiments is intended to complement, not replace or supersede, the preceding description. All steps in the methods described herein are also relevant for use in any of these methods. All embodiments for the methods described herein also apply to use in such methods.
[0444] Embodiment 1. A crystalline composition comprising SEQ ID NO:3 and a ligand, characterized by space group p22121 and unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°.
[0445] Embodiment 2. The ligand is a compound of formula (I)
[0446] [ka] or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
[0447] Embodiment 3. A method for identifying and / or designing candidate inhibitors of BTK, comprising: generating a three-dimensional structure of the binding site of BTK on a computer, the three-dimensional structural coordinates having unit cell parameters and space group parameters of the crystalline composition of claim 1; using the three-dimensional structure to design or select candidate inhibitors; contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK; A method comprising:
[0448] Embodiment 4 The method of embodiment 3, wherein the candidate inhibitor forms a direct covalent bond with Cys481.
[0449] Embodiment 5. The method of embodiment 3, wherein the candidate inhibitor forms a hydrogen bond with Lys430.
[0450] Embodiment 6 The method of embodiment 3, wherein the candidate inhibitor forms a hydrogen bond with Met477.
[0451] Embodiment 7. A method for identifying and / or designing candidate inhibitors using human BTK crystals comprising the human BTK protein, comprising: a) preparing a crystalline composition according to claim 2; b) soaking another candidate inhibitor into the crystalline composition and displacing the compound of formula (I) to form an inhibitor-crystal complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); and d) designing or selecting candidate inhibitors using the structural coordinates obtained in step c). e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK; A method comprising:
[0452] Embodiment 8. (i) human BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, and (ii) Human BTK amino acid residues according to Table 2 1. A method for designing a compound or complex that interacts with a binding pocket or binding domain selected from the group consisting of: (a) A compound of formula (I)
[0453] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of the backbone atoms is about 2.5 Å or less; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) optionally repeating steps (c) through (e) with one or more additional chemicals, selecting the additional chemicals based on the quantified association of all of the first chemical, the second chemical, and the one or more additional chemicals; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the one or more additional chemicals with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the one or more additional chemicals; (h) assembling by model building a compound or complex from the first chemical, the second chemical and one or more additional chemicals that interacts with the binding pocket or binding domain.
[0454] Embodiment 9. A method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0455] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of the amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root-mean-square deviation from the backbone atoms of less than ±2.0 Å; (d) determining the binding site of the human BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify candidate inhibitors that interact with the binding site.
[0456] EMBODIMENT 10. 10. The method of embodiment 9, further comprising the step of: (f) contacting the identified candidate inhibitor with BTK protein to determine the effect of the inhibitor on BTK activity.
[0457] Embodiment 11. The method of embodiment 9, wherein the binding site of the BTK protein determined in step (d) comprises structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, with a root mean square deviation of less than or equal to ±2.0 Å.
[0458] Embodiment 12. A method of using a crystal comprising the BTK binding pocket or the BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I)
[0459] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) selecting potential inhibitors by performing rational drug design using the determined three-dimensional structure of the crystal, wherein the selecting step is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with the kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase.
[0460] Embodiment 13. A method of designing a compound or complex that interacts with the BTK binding pocket or BTK binding domain, comprising: (a) A compound of formula (I)
[0461] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal being characterized by space group p22121 with unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing the structural coordinates of the binding pocket or binding domain of the crystal of step (a) according to Table 2 onto a computer capable of generating three-dimensional structural information from the structural coordinates; (c) computationally docking a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting the first chemical, the second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of the first chemical, the second chemical, and the at least one additional chemical with respect to the binding pocket or binding domain using a three-dimensional graphical representation of the binding pocket or binding domain, and the first chemical, the second chemical, and the at least one additional chemical; (h) assembling by model building a compound or complex from the first chemical, the second chemical and at least one additional chemical that interacts with the binding pocket or binding domain.
[0462] Embodiment 14. A method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I)
[0463] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structure coordinates obtained in step (b); and (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK.
[0464] Embodiment 15. A method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I)
[0465] [ka] or a pharma- ceutical acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystals from step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of a molecular complex comprising the binding sites for amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing the candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK.
[0466] Sequence Listing Number of sequence numbers: 3
[0467] SEQ ID NO:1 LENGTH:1500 TYPE:DNA Living organism: Human (Homo sapiens) Sequence: 1 atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaacccac tcgacttctt ttggaatatc ttgaagaaaa atatgaagag catttgtatg agcgcgatga aggtgataaa tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa acatatttaa atggtgatca tgtaacccat cctgacttca tgttgtatga cgctcttgat gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca tggccttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat acgaccgaaa acctgtattt tcagggcctg ggatacggat catgggaaat tgatccaaag gacctgacct tcttgaagga gctggggact ggacaatttg gggtagtgaa gtatggggaaa tggagaggcc agtacgacgt ggccatcaag atgatcaaag aaggctccat gtctgaagat gaattcattg aagaagccaa agtcatgatg aatctttccc atgagaagct ggtgcagttg tatggcgtct gcaccaagca gcgccccatc ttcatcatca ctgagtacat ggccaatggc tgcctcctga actacctgag ggagatgcgc caccgcttc agactcagca gctgctagag atgtgcaagg atgtctgtga agccatggaa tacctggagt caaagcagtt ccttcaccga gacctggcag ctcgaaactg tttggtaaac gatcaaggag ttgttaaagt atctgatttc ggcctgtcca ggtatgtcct ggatgatgaa tacacaagct cagtaggctc caaatttcca gtccggtggt ccccaccgga agtcctgatg tatagcaagt tcagcagcaa atctgacatt tgggcttttg gggttttgat gtgggaaatt tactccctgg ggaagatgcc atatgagaga tttactaaca gtgagactgc tgaacacatt gcccaaggcc tacgtctcta caggcctcat ctggcttcag agaaggtata taccatcatg tacagttgtt ggcatgagaa agcagatgag cgtcccactt tcaaaattct tctgagcaat attctagatg tcatggatga agaatcctga
[0468] SEQ ID NO:2 LENGTH:228 TYPE:PRT ORGANISM:Homo sapiens SEQUENCE:2 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD TTENLYFQ
[0469] SEQ ID NO:3 LENGTH:271 TYPE:PRT Living organism: Human (Homo sapiens) Array:3 GLGYGSWEID PKDLTFLKEL GTGQFGVVKY GKWRGQYDVA IKMIKEGSMS EDEFIEEAKV MMNLSHEKLV QLYGVCTKQR PIFIITEYMA NGCLLNYLRE MRHRFQTQQL LEMCKDVCEA MEYLESKQFL HRDLAARNCL VNDQGVVKVS DFGLSRYVLD DEYTSSVGSK FPVRWSPPEV LMYSKFSSKS DIWAFGVLMW EIYSLGKMPY ERFTNSETAE HIAQGLRLYR PHLASEKVYT IMYSCWHEKA DERPTFKILL SNILDVMDEE S
Claims
1. A crystalline composition comprising SEQ ID NO:3 and a ligand, characterized by space group p22121 and with unit cell parameters a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°.
2. The ligand is a compound of formula (I) 【Chemistry 1】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof.
3. 1. A method for identifying and / or designing a candidate inhibitor of BTK, comprising: generating a three-dimensional structure of a binding site of BTK on a computer, said three-dimensional structural coordinates having unit cell parameters and space group parameters of the crystalline composition of claim 1; using said three-dimensional structure to design or select candidate inhibitors; contacting said candidate inhibitor with human BTK and measuring the ability of said candidate inhibitor to bind to BTK; A method comprising:
4. The method of claim 3, wherein the candidate inhibitor forms a direct covalent bond with Cys481.
5. The method of claim 3, wherein the candidate inhibitor forms a hydrogen bond with Lys430.
6. The method of claim 3, wherein the candidate inhibitor forms a hydrogen bond with Met477.
7. 1. A method for identifying and / or designing candidate inhibitors using a human BTK crystal comprising a human BTK protein, comprising: a) preparing a crystalline composition according to claim 2; b) soaking another candidate inhibitor into the crystalline composition to displace the compound of formula (I) to form an inhibitor-crystalline complex; c) determining the three-dimensional structural coordinates of the inhibitor-crystal complex prepared in step b); and d) using the structural coordinates obtained in step c) to design or select candidate inhibitors. e) contacting the candidate inhibitor with human BTK and measuring the ability of the candidate inhibitor to bind to BTK; A method comprising:
8. (i) human BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, and (ii) Human BTK amino acid residues according to Table 2 A method for designing a compound or complex which interacts with a binding pocket or binding domain selected from the group consisting of: (a) A compound of formula (I) 【Chemistry 2】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2, wherein the root mean square deviation of backbone atoms is less than or equal to about 2.5 Å; (c) using the computer to dock a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) optionally repeating steps (c) through (e) with one or more additional chemicals, selecting the additional chemicals based on the quantified association of all of the first chemical, the second chemical, and the one or more additional chemicals; (g) optionally visually inspecting on a computer screen the interrelationship of said first chemical, said second chemical, and said one or more additional chemicals with respect to said binding pocket or binding domain using a three-dimensional graphical representation of said binding pocket or binding domain, and said first chemical, said second chemical, and said one or more additional chemicals; (h) assembling, by model building, from the first chemical entity, the second chemical entity, and the one or more additional chemical entities, a compound or complex that interacts with the binding pocket or binding domain; A method comprising:
9. 1. A method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I) 【Chemistry 3】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) obtaining structural coordinates of amino acids of the crystal of step (a) according to Table 2; (c) generating a three-dimensional model of the BTK protein using the structural coordinates of the amino acids obtained in step (b), the three-dimensional model having a root mean square deviation from backbone atoms of ±2.0 Å or less; (d) determining a binding site of the human BTK protein from the three-dimensional model; and (e) performing a computer fitting analysis to identify said candidate inhibitors that interact with said binding site; A method comprising:
10. 10. The method of claim 9, further comprising the step of: (f) contacting the identified candidate inhibitor with the BTK protein to determine the effect of the inhibitor on BTK activity.
11. 10. The method of claim 9, wherein the binding site of the BTK protein determined in step (d) comprises structural coordinates of BTK amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539, and Phe540 according to Table 2, wherein the root mean square deviation is less than or equal to ±2.0 Å.
12. 1. A method of using a crystal comprising a BTK binding pocket or a BTK binding domain in an inhibitor screening assay, comprising: (a) A compound of formula (I) 【Chemistry 4】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2; (c) using the determined three-dimensional structure of the crystal to select potential inhibitors by performing rational drug design, wherein said selecting is performed in conjunction with computer modeling; (d) contacting the potential inhibitor with a kinase; (e) detecting the ability of the potential inhibitor to inhibit the enzymatic activity of the kinase; A method comprising:
13. 1. A method for designing a compound or complex that interacts with a BTK binding pocket or a BTK binding domain, comprising: (a) A compound of formula (I) 【Chemistry 5】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by the space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) providing structural coordinates of the binding pocket or binding domain of the crystal of step (a) on a computer capable of generating three-dimensional structural information from the structural coordinates according to Table 2; (c) using the computer to dock a first chemical entity into the binding pocket or portion of the binding domain; (d) docking at least a second chemical entity into the binding pocket or another portion of the binding domain; (e) quantifying the association between the first chemical entity or the second chemical entity and the portion of the binding pocket or binding domain; (f) repeating steps (c) through (e) with at least one additional chemical, selecting a first chemical, a second chemical, and the at least one additional chemical based on the quantified association of all of the first chemical, the second chemical, and the at least one additional chemical; (g) optionally visually inspecting on a computer screen the interrelationship of said first chemical, said second chemical and said at least one additional chemical with respect to said binding pocket or binding domain using a three-dimensional graphical representation of said binding pocket or binding domain, and said first chemical, said second chemical and said at least one additional chemical; (h) assembling, by model building, from the first chemical entity, the second chemical entity, and the at least one additional chemical entity, a compound or complex that interacts with the binding pocket or binding domain; A method comprising:
14. 1. A method for identifying a candidate inhibitor that interacts with a binding site of a BTK protein, comprising: (a) A compound of formula (I) 【Chemistry 6】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystal of step (a); and (c) generating a three-dimensional structure of the crystallized BTK protein generated in step (a) using the structural coordinates obtained in step (b); (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing said candidate inhibitor; (f) contacting the candidate inhibitor with a human BTK protein to determine the ability of the candidate inhibitor to bind to human BTK. A method comprising:
15. 1. A method for identifying a candidate inhibitor that interacts with a binding site of a human BTK protein, comprising: (a) A compound of formula (I) 【Chemistry 7】 or a pharma- ceutically acceptable salt, hydrate, polymorph, or solvate thereof, wherein the BTK comprises SEQ ID NO:3, the crystal is characterized by space group p22121 and has unit cell parameters of a=38.155±2 Å, b=72.394±2 Å, c=103.946±2 Å, a=90°, b=90°, g=90°; (b) determining the three-dimensional structural coordinates of BTK using the crystal of step (a); and (c) using the structural coordinates obtained in step (b) to generate a three-dimensional structure of a molecular complex comprising the binding sites of amino acid residues Leu408, Gly409, Thr410, Gly411, Val416, Ala428, Lys430, Asn439, Met449, Leu452, Val458, Ile472, Thr474, Glu475, Tyr476, Met477, Gly480, Cys481, Asn484, Arg525, Leu528, Ser538, Asp539 and Phe540 according to Table 2, wherein the root mean square deviation of the backbone atoms is less than or equal to about 2.5 Å; (d) using the three-dimensional structure to design or select candidate inhibitors; (e) synthesizing said candidate inhibitor; (f) contacting the candidate inhibitor with BTK to determine the ability of the candidate inhibitor to bind to BTK. A method comprising:
Citation Information
Patent Citations
Crystal structure of the BTK kinase domain
WO2003016338A1
